BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Cited by in Crossref: 473] [Cited by in F6Publishing: 451] [Article Influence: 78.8] [Reference Citation Analysis]
Number Citing Articles
1 Laschos K, Lampropoulou DI, Aravantinos G, Piperis M, Filippou D, Theodoropoulos G, Gazouli M. Exosomal noncoding RNAs in cholangiocarcinoma: Laboratory noise or hope? World J Gastrointest Surg 2020; 12(10): 407-424 [PMID: 33194090 DOI: 10.4240/wjgs.v12.i10.407] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Yu W, Xiang Y, Luo G, Zhao X, Xiao B, Cheng Y, Feng C, Duan C, Xia X, Wong VKW, Dai R. Salubrinal Enhances Doxorubicin Sensitivity in Human Cholangiocarcinoma Cells Through Promoting DNA Damage. Cancer Biother Radiopharm 2018;33:258-65. [PMID: 29957018 DOI: 10.1089/cbr.2018.2447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Cholangiocarcinoma Working Group. Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part II: Treatment. Dig Liver Dis 2020;52:1430-42. [PMID: 32952071 DOI: 10.1016/j.dld.2020.08.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
4 Siripanthong S, Techasen A, Nantasenamat C, Malik AA, Sithithaworn P, Leelayuwat C, Jumnainsong A. Production and characterization of antibody against Opisthorchis viverrini via phage display and molecular simulation. PLoS One 2021;16:e0248887. [PMID: 33755687 DOI: 10.1371/journal.pone.0248887] [Reference Citation Analysis]
5 Al Mahjoub A, Bouvier V, Menahem B, Bazille C, Fohlen A, Alves A, Mulliri A, Launoy G, Lubrano J. Epidemiology of intrahepatic, perihilar, and distal cholangiocarcinoma in the French population. European Journal of Gastroenterology & Hepatology 2019;31:678-84. [DOI: 10.1097/meg.0000000000001337] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
6 Kennedy L, Hargrove L, Demieville J, Francis N, Seils R, Villamaria S, Francis H. Recent Advances in Understanding Cholangiocarcinoma. F1000Res 2017;6:1818. [PMID: 29067165 DOI: 10.12688/f1000research.12118.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
7 Tan EK, Taner T, Heimbach JK, Gores GJ, Rosen CB. Liver Transplantation for Peri-hilar Cholangiocarcinoma.J Gastrointest Surg. 2020;24:2679-2685. [PMID: 32671802 DOI: 10.1007/s11605-020-04721-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
8 Kommalapati A, Tella SH, Goyal G, Borad M, Alberts SR, Roberts L, Hubbard JM, Durgin L, Cleary S, Mahipal A. Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma. HPB (Oxford) 2019;21:379-86. [PMID: 30266490 DOI: 10.1016/j.hpb.2018.08.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Cholangiocarcinoma Working Group. Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part I: Classification, diagnosis and staging. Dig Liver Dis 2020;52:1282-93. [PMID: 32893173 DOI: 10.1016/j.dld.2020.06.045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
10 Sarcognato S, Jong IEM, Fabris L, Cadamuro M, Guido M. Necroptosis in Cholangiocarcinoma. Cells 2020;9:E982. [PMID: 32326539 DOI: 10.3390/cells9040982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Gou Q, Wu L, Cui W, Mo Z, Zeng D, Gan L, He J, Mai Q, Shi F, Chen M, Sun Z, Liu Y, Wu J, Chen X, Zhuang W, Xu R, Li W, Cai Q, Zhang J, Chen X, Li J, Zhou Z. Stent placement combined with intraluminal radiofrequency ablation and hepatic arterial infusion chemotherapy for advanced biliary tract cancers with biliary obstruction: a multicentre, retrospective, controlled study. Eur Radiol 2021;31:5851-62. [PMID: 33585991 DOI: 10.1007/s00330-021-07716-0] [Reference Citation Analysis]
12 Rattanaburee T, Thongpanchang T, Wongma K, Tedasen A, Sukpondma Y, Graidist P. Anticancer activity of synthetic (±)-kusunokinin and its derivative (±)-bursehernin on human cancer cell lines. Biomed Pharmacother 2019;117:109115. [PMID: 31220743 DOI: 10.1016/j.biopha.2019.109115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
13 Koustas E, Trifylli EM, Sarantis P, Papavassiliou AG, Karamouzis MV. Role of autophagy in cholangiocarcinoma: An autophagy-based treatment strategy. World J Gastrointest Oncol 2021; 13(10): 1229-1243 [PMID: 34721764 DOI: 10.4251/wjgo.v13.i10.1229] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52:1898-1907. [PMID: 33268834 DOI: 10.1038/s12276-020-00527-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
15 Casadio M, Cardinale V, Klümpen H, Morement H, Lacasta A, Koerkamp B, Banales J, Alvaro D, Valle J, Lamarca A. Setup of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). ESMO Open 2022;7:100377. [DOI: 10.1016/j.esmoop.2021.100377] [Reference Citation Analysis]
16 Kim SY, Lee HS, Bang SM, Han DH, Hwang HK, Choi GH, Chung MJ, Kim SU. Serum Dickkopf-1 in Combined with CA 19-9 as a Biomarker of Intrahepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:1828. [PMID: 33921232 DOI: 10.3390/cancers13081828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Angenard G, Merdrignac A, Louis C, Edeline J, Coulouarn C. Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma. Dig Liver Dis. 2019;51:1337-1343. [PMID: 31040073 DOI: 10.1016/j.dld.2019.03.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
18 Sato K, Francis H, Zhou T, Meng F, Kennedy L, Ekser B, Baiocchi L, Onori P, Mancinelli R, Gaudio E, Franchitto A, Glaser S, Alpini G. Neuroendocrine Changes in Cholangiocarcinoma Growth. Cells 2020;9:E436. [PMID: 32069926 DOI: 10.3390/cells9020436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
19 Lang SA, Bednarsch J, Joechle K, Amygdalos I, Czigany Z, Heij L, Ulmer TF, Neumann UP. Prognostic biomarkers for cholangiocarcinoma (CCA): state of the art. Expert Rev Gastroenterol Hepatol 2021;15:497-510. [PMID: 33970740 DOI: 10.1080/17474124.2021.1912591] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Sasaki K, Margonis GA, Andreatos N, Bagante F, Weiss M, Barbon C, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Koerkamp BG, Guglielmi A, Itaru E, Aucejo FN, Pawlik TM. Preoperative Risk Score and Prediction of Long-Term Outcomes after Hepatectomy for Intrahepatic Cholangiocarcinoma. Journal of the American College of Surgeons 2018;226:393-403. [DOI: 10.1016/j.jamcollsurg.2017.12.011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
21 Hu ZG, Zheng CW, Su HZ, Zeng YL, Lin CJ, Guo ZY, Zhong FD, Yuan GD, He SQ. MicroRNA-329-mediated PTTG1 downregulation inactivates the MAPK signaling pathway to suppress cell proliferation and tumor growth in cholangiocarcinoma. J Cell Biochem 2019;120:9964-78. [PMID: 30582202 DOI: 10.1002/jcb.28279] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
22 Fang T, Wang H, Wang Y, Lin X, Cui Y, Wang Z. Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma. Dis Markers. 2019;2019:6016931. [PMID: 30863466 DOI: 10.1155/2019/6016931] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
23 Fabris L, Perugorria MJ, Mertens J, Björkström NK, Cramer T, Lleo A, Solinas A, Sänger H, Lukacs-Kornek V, Moncsek A, Siebenhüner A, Strazzabosco M. The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver Int 2019;39 Suppl 1:63-78. [PMID: 30907492 DOI: 10.1111/liv.14098] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 15.5] [Reference Citation Analysis]
24 Mima K, Nakagawa S, Sawayama H, Ishimoto T, Imai K, Iwatsuki M, Hashimoto D, Baba Y, Yamashita YI, Yoshida N, Chikamoto A, Baba H. The microbiome and hepatobiliary-pancreatic cancers.Cancer Lett. 2017;402:9-15. [PMID: 28527946 DOI: 10.1016/j.canlet.2017.05.001] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 11.4] [Reference Citation Analysis]
25 Chen Q, Li J, Jin B, Wu X, Shi Y, Xu H, Zheng Y, Wang Y, Du S, Lu X, Sang X, Mao Y. Prognostic Nomogram That Predicts Overall Survival of Patients with Distal Cholangiocarcinoma After Pancreatoduodenectomy. Cancer Manag Res 2020;12:10303-10. [PMID: 33116885 DOI: 10.2147/CMAR.S276393] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Rangarajan K, Simmons G, Manas D, Malik H, Hamady ZZ. Systemic adjuvant chemotherapy for cholangiocarcinoma surgery: A systematic review and meta-analysis. Eur J Surg Oncol. 2020;46:684-693. [PMID: 31761507 DOI: 10.1016/j.ejso.2019.11.499] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
27 Zhang J, Su G, Tang Z, Wang L, Fu W, Zhao S, Ba Y, Bai B, Yue P, Lin Y, Bai Z, Hu J, Meng W, Qiao L, Li X, Xie X. Curcumol Exerts Anticancer Effect in Cholangiocarcinoma Cells via Down-Regulating CDKL3. Front Physiol 2018;9:234. [PMID: 29615928 DOI: 10.3389/fphys.2018.00234] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
28 Lustri AM, Di Matteo S, Fraveto A, Costantini D, Cantafora A, Napoletano C, Bragazzi MC, Giuliante F, De Rose AM, Berloco PB, Grazi GL, Carpino G, Alvaro D. TGF-β signaling is an effective target to impair survival and induce apoptosis of human cholangiocarcinoma cells: A study on human primary cell cultures. PLoS One 2017;12:e0183932. [PMID: 28873435 DOI: 10.1371/journal.pone.0183932] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
29 Qasrawi A, Abughanimeh O, Abu Ghanimeh M, Arora-Elder S, Yousef O, Tamimi T. Intrahepatic Cholangiocarcinoma Masquerading as Acute Fatty Liver of Pregnancy: A Case Report and Review of the Literature. Case Reports Hepatol 2018;2018:6939747. [PMID: 29682369 DOI: 10.1155/2018/6939747] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
30 Erice O, Vallejo A, Ponz-Sarvise M, Saborowski M, Vogel A, Calvisi DF, Saborowski A, Vicent S. Genetic Mouse Models as In Vivo Tools for Cholangiocarcinoma Research. Cancers (Basel) 2019;11:E1868. [PMID: 31769429 DOI: 10.3390/cancers11121868] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
31 Lamarca A, Santos-Laso A, Utpatel K, La Casta A, Stock S, Forner A, Adeva J, Folseraas T, Fabris L, Macias RIR, Krawczyk M, Krawczyk M, Cardinale V, Braconi C, Alvaro D, Evert M, Banales JM, Valle JW; Group: on behalf of the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. Hepatology 2021;73:2311-25. [PMID: 33073396 DOI: 10.1002/hep.31598] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
32 Fabris L, Sato K, Alpini G, Strazzabosco M. The Tumor Microenvironment in Cholangiocarcinoma Progression. Hepatology 2021;73 Suppl 1:75-85. [PMID: 32500550 DOI: 10.1002/hep.31410] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
33 Vigano L, Soldani C, Franceschini B, Cimino M, Lleo A, Donadon M, Roncalli M, Aghemo A, Di Tommaso L, Torzilli G. Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery. J Gastrointest Surg 2019;23:2216-24. [PMID: 30843133 DOI: 10.1007/s11605-019-04111-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
34 Yeh Y, Lei H, Chen M, Ho H, Chiu L, Li C, Wang Y. C-Reactive Protein (CRP) is a Promising Diagnostic Immunohistochemical Marker for Intrahepatic Cholangiocarcinoma and is Associated With Better Prognosis. American Journal of Surgical Pathology 2017;41:1630-41. [DOI: 10.1097/pas.0000000000000957] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
35 Iyer P, Chen MH, Goyal L, Denlinger CS. Targets for therapy in biliary tract cancers: the new horizon of personalized medicine. Chin Clin Oncol 2020;9:7. [PMID: 32146818 DOI: 10.21037/cco.2019.12.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer 2021;21:541-57. [PMID: 34326518 DOI: 10.1038/s41568-021-00383-9] [Reference Citation Analysis]
37 Neuzillet C, Emery C, Teissier C, Bouée S, Lièvre A. Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis. The Lancet Regional Health - Europe 2022;15:100324. [DOI: 10.1016/j.lanepe.2022.100324] [Reference Citation Analysis]
38 Urban SK, Sänger H, Krawczyk M, Julich-Haertel H, Willms A, Ligocka J, Azkargorta M, Mocan T, Kahlert C, Kruk B, Jankowski K, Patkowski W, Krawczyk M, Zieniewicz K, Hołówko W, Krupa Ł, Rzucidło M, Gutkowski K, Wystrychowski W, Król R, Raszeja-Wyszomirska J, Słomka A, Schwab R, Wöhler A, Gonzalez-Carmona MA, Gehlert S, Sparchez Z, Banales JM, Strassburg CP, Lammert F, Milkiewicz P, Kornek M. Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer differentiation. Liver Int 2020;40:3103-16. [PMID: 32614460 DOI: 10.1111/liv.14585] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
39 Hodgson A, Almansouri Z, Adeyi O, Fischer SE. Gross and microscopic changes of liver neoplasms and background hepatic structures following neoadjuvant therapy. J Clin Pathol 2019;72:112-9. [PMID: 30670563 DOI: 10.1136/jclinpath-2018-205596] [Reference Citation Analysis]
40 Cigliano A, Pilo MG, Mela M, Ribback S, Dombrowski F, Pes GM, Cossu A, Evert M, Calvisi DF, Utpatel K. Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma. Medicina (Kaunas) 2019;56:E1. [PMID: 31861475 DOI: 10.3390/medicina56010001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
41 Okusaka T. Cholangiocarcinoma: is it time for a revolution? Expert Rev Gastroenterol Hepatol 2021;15:467-70. [PMID: 33840344 DOI: 10.1080/17474124.2021.1915766] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Marcus R, Ferri-Borgogno S, Hosein A, Foo WC, Ghosh B, Zhao J, Rajapakshe K, Brugarolas J, Maitra A, Gupta S. Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:5709. [PMID: 34830866 DOI: 10.3390/cancers13225709] [Reference Citation Analysis]
43 Tsai S, Gamblin TC. Molecular Characteristics of Biliary Tract and Primary Liver Tumors. Surg Oncol Clin N Am 2019;28:685-93. [PMID: 31472913 DOI: 10.1016/j.soc.2019.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
44 Torzilli G, Viganò L, Fontana A, Procopio F, Terrone A, Cimino MM, Donadon M, Del Fabbro D. Oncological outcome of R1 vascular margin for mass-forming cholangiocarcinoma. A single center observational cohort analysis. HPB (Oxford) 2020;22:570-7. [PMID: 31530450 DOI: 10.1016/j.hpb.2019.08.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
45 Haznadar M, Diehl CM, Parker AL, Krausz KW, Bowman ED, Rabibhadana S, Forgues M, Bhudhisawasdi V, Gonzalez FJ, Mahidol C, Budhu A, Wang XW, Ruchirawat M, Harris CC. Urinary Metabolites Diagnostic and Prognostic of Intrahepatic Cholangiocarcinoma. Cancer Epidemiol Biomarkers Prev 2019;28:1704-11. [PMID: 31358519 DOI: 10.1158/1055-9965.EPI-19-0453] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
46 Correnti M, Raggi C. Stem-like plasticity and heterogeneity of circulating tumor cells: current status and prospect challenges in liver cancer. Oncotarget 2017;8:7094-115. [PMID: 27738343 DOI: 10.18632/oncotarget.12569] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
47 Fragkou N, Sideras L, Panas P, Emmanouilides C, Sinakos E. Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence? World J Gastroenterol 2021; 27(27): 4252-4275 [PMID: 34366604 DOI: 10.3748/wjg.v27.i27.4252] [Reference Citation Analysis]
48 Nakagawa H, Hayata Y, Yamada T, Kawamura S, Suzuki N, Koike K. Peribiliary Glands as the Cellular Origin of Biliary Tract Cancer. Int J Mol Sci. 2018;19. [PMID: 29895797 DOI: 10.3390/ijms19061745] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
49 Mordvinov VA, Minkova GA, Kovner AV, Ponomarev DV, Lvova MN, Zaparina O, Romanenko SA, Shilov AG, Pakharukova MY. A tumorigenic cell line derived from a hamster cholangiocarcinoma associated with Opisthorchis felineus liver fluke infection. Life Sci 2021;277:119494. [PMID: 33862109 DOI: 10.1016/j.lfs.2021.119494] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Limpawattana P, Theerakulpisut D, Wirasorn K, Sookprasert A, Khuntikeo N, Chindaprasirt J. The impact of skeletal muscle mass on survival outcome in biliary tract cancer patients. PLoS One 2018;13:e0204985. [PMID: 30303998 DOI: 10.1371/journal.pone.0204985] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
51 Zhou M, Wang C, Lu S, Xu Y, Li Z, Jiang H, Ma Y. Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target. EBioMedicine 2021;67:103375. [PMID: 33993051 DOI: 10.1016/j.ebiom.2021.103375] [Reference Citation Analysis]
52 Trombetta D, Parente P, Latiano TP, Fabrizio FP, Muscarella LA. Identification of EML4-ALK fusion in a sporadic case of cholangiocarcinoma. European Journal of Internal Medicine 2020;71:92-4. [DOI: 10.1016/j.ejim.2019.10.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Goeppert B, Toth R, Singer S, Albrecht T, Lipka DB, Lutsik P, Brocks D, Baehr M, Muecke O, Assenov Y, Gu L, Endris V, Stenzinger A, Mehrabi A, Schirmacher P, Plass C, Weichenhan D, Roessler S. Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma. Hepatology 2019;69:2091-106. [PMID: 30615206 DOI: 10.1002/hep.30493] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
54 Rodrigues MA, Gomes DA, Cosme AL, Sanches MD, Resende V, Cassali GD. Inositol 1,4,5-trisphosphate receptor type 3 (ITPR3) is overexpressed in cholangiocarcinoma and its expression correlates with S100 calcium-binding protein A4 (S100A4). Biomed Pharmacother 2021;145:112403. [PMID: 34798470 DOI: 10.1016/j.biopha.2021.112403] [Reference Citation Analysis]
55 Westphalen CB, Preinfalk A, Kruger S, Haas M, Renz BW, Riener M, Weber A, Kirchner T, Werner J, Heinemann V, von Bergwelt-baildon M, Baba HA, Siveke JT, Ormanns S, Boeck S. Neurotrophic tropomyosin receptor kinase (NTRK) and nerve growth factor (NGF) are not expressed in Caucasian patients with biliary tract cancers: pooled data from three independent cohorts. Clin Transl Oncol 2019;21:1108-11. [DOI: 10.1007/s12094-018-02030-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
56 Izquierdo-sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Klümpen H, Adeva J, Vogel A, Lleo A, Fabris L, Ponz-sarvise M, Brustia R, Cardinale V, Braconi C, Vidili G, Jamieson NB, Macias RI, Jonas JP, Marzioni M, Hołówko W, Folseraas T, Kupčinskas J, Sparchez Z, Krawczyk M, Krupa Ł, Scripcariu V, Grazi GL, Landa-magdalena A, Ijzermans JN, Evert K, Erdmann JI, López-lópez F, Saborowski A, Scheiter A, Santos-laso A, Carpino G, Andersen JB, Marin JJ, Alvaro D, Bujanda L, Forner A, Valle JW, Koerkamp BG, Banales JM. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2021.12.010] [Reference Citation Analysis]
57 Rhee H, Kim M, Park YN, An C. A proposal of imaging classification of intrahepatic mass-forming cholangiocarcinoma into ductal and parenchymal types: clinicopathologic significance. Eur Radiol 2019;29:3111-21. [DOI: 10.1007/s00330-018-5898-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
58 Sungwan P, Lert-Itthiporn W, Silsirivanit A, Klinhom-On N, Okada S, Wongkham S, Seubwai W. Bioinformatics analysis identified CDC20 as a potential drug target for cholangiocarcinoma. PeerJ 2021;9:e11067. [PMID: 33777535 DOI: 10.7717/peerj.11067] [Reference Citation Analysis]
59 Sripa B, Seubwai W, Vaeteewoottacharn K, Sawanyawisuth K, Silsirivanit A, Kaewkong W, Muisuk K, Dana P, Phoomak C, Lert-Itthiporn W, Luvira V, Pairojkul C, Teh BT, Wongkham S, Okada S, Chamgramol Y. Functional and genetic characterization of three cell lines derived from a single tumor of an Opisthorchis viverrini-associated cholangiocarcinoma patient. Hum Cell 2020;33:695-708. [PMID: 32207095 DOI: 10.1007/s13577-020-00334-w] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
60 Kim HD, Jeong S, Park S, Lee YJ, Ju YS, Kim D, Song GW, Lee JH, Kim SY, Shin J, Shin EC, Hwang S, Yoo C, Park SH. Implication of CD69+ CD103+ tissue-resident-like CD8+ T cells as a potential immunotherapeutic target for cholangiocarcinoma. Liver Int 2021;41:764-76. [PMID: 33548061 DOI: 10.1111/liv.14814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Hu G, Liu Q, Ma JY, Liu CY. Prognostic Significance of Platelet-to-Lymphocyte Ratio in Cholangiocarcinoma: A Meta-Analysis. Biomed Res Int 2018;2018:7375169. [PMID: 30539019 DOI: 10.1155/2018/7375169] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
62 Wu Y, Hayat K, Hu Y, Yang J. Long Non-Coding RNAs as Molecular Biomarkers in Cholangiocarcinoma. Front Cell Dev Biol 2022;10:890605. [DOI: 10.3389/fcell.2022.890605] [Reference Citation Analysis]
63 Alanazi SA, Alanazi F, Haq N, Shakeel F, Badran MM, Harisa GI. Lipoproteins-Nanocarriers as a Promising Approach for Targeting Liver Cancer: Present Status and Application Prospects. Curr Drug Deliv 2020;17:826-44. [PMID: 32026776 DOI: 10.2174/1567201817666200206104338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
64 Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018;36:276-282. [PMID: 29182496 DOI: 10.1200/jco.2017.75.5009] [Cited by in Crossref: 249] [Cited by in F6Publishing: 130] [Article Influence: 49.8] [Reference Citation Analysis]
65 Onsurathum S, Haonon O, Pinlaor P, Pairojkul C, Khuntikeo N, Thanan R, Roytrakul S, Pinlaor S. Proteomics detection of S100A6 in tumor tissue interstitial fluid and evaluation of its potential as a biomarker of cholangiocarcinoma. Tumour Biol 2018;40:101042831876719. [DOI: 10.1177/1010428318767195] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
66 Chen C, Nelson LJ, Ávila MA, Cubero FJ. Mitogen-Activated Protein Kinases (MAPKs) and Cholangiocarcinoma: The Missing Link. Cells 2019;8:E1172. [PMID: 31569444 DOI: 10.3390/cells8101172] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
67 Correnti M, Cappon A, Pastore M, Piombanti B, Lori G, Oliveira DVPN, Munoz-Garrido P, Lewinska M, Andersen JB, Coulouarn C, Sulpice L, Peraldo Neia C, Cavalloni G, Quarta S, Biasiolo A, Fassan M, Ramazzotti M, Parri M, Recalcati S, di Tommaso L, Campani C, Invernizzi P, Torzilli G, Marra F, Pontisso P, Raggi C. The protease-inhibitor SerpinB3 as a critical modulator of the stem-like subset in human cholangiocarcinoma. Liver Int 2021. [PMID: 34478594 DOI: 10.1111/liv.15049] [Reference Citation Analysis]
68 Chen Z, Pu L, Gao W, Zhang L, Han G, Zhu Q, Li X, Wu J, Wang X. Influence of marital status on the survival of adults with extrahepatic/intrahepatic cholangiocarcinoma. Oncotarget 2017;8:28959-70. [PMID: 28415824 DOI: 10.18632/oncotarget.16330] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
69 Zhou Z, Wang P, Sun R, Li J, Hu Z, Xin H, Luo C, Zhou J, Fan J, Zhou S. Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3. J Immunother Cancer 2021;9:e001946. [PMID: 33692217 DOI: 10.1136/jitc-2020-001946] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
70 Massani M, Bonariol L, Stecca T. Hepatic Arterial Infusion Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma, a Comprehensive Review. J Clin Med 2021;10:2552. [PMID: 34207700 DOI: 10.3390/jcm10122552] [Reference Citation Analysis]
71 Akamatsu N, Sakamoto Y, Hasegawa K. Liver transplantation for the solitary intrahepatic cholangiocarcinoma less than 2 cm in diameter. Hepatobiliary Surg Nutr 2017;6:332-4. [PMID: 29152481 DOI: 10.21037/hbsn.2017.05.10] [Reference Citation Analysis]
72 Recalcati S, Correnti M, Gammella E, Raggi C, Invernizzi P, Cairo G. Iron Metabolism in Liver Cancer Stem Cells. Front Oncol 2019;9:149. [PMID: 30941302 DOI: 10.3389/fonc.2019.00149] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
73 Raggi C, Correnti M, Sica A, Andersen JB, Cardinale V, Alvaro D, Chiorino G, Forti E, Glaser S, Alpini G, Destro A, Sozio F, Di Tommaso L, Roncalli M, Banales JM, Coulouarn C, Bujanda L, Torzilli G, Invernizzi P. Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. J Hepatol. 2017;66:102-115. [PMID: 27593106 DOI: 10.1016/j.jhep.2016.08.012] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 12.0] [Reference Citation Analysis]
74 Panayotova GG, Paterno F, Guarrera JV, Lunsford KE. Liver Transplantation for Cholangiocarcinoma: Insights into the Prognosis and the Evolving Indications. Curr Oncol Rep. 2020;22:49. [PMID: 32297105 DOI: 10.1007/s11912-020-00910-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
75 Yoon SB, Moon SH, Ko SW, Lim H, Kang HS, Kim JH. Brush Cytology, Forceps Biopsy, or Endoscopic Ultrasound-Guided Sampling for Diagnosis of Bile Duct Cancer: A Meta-Analysis. Dig Dis Sci 2021. [PMID: 34263382 DOI: 10.1007/s10620-021-07138-4] [Reference Citation Analysis]
76 Vaeteewoottacharn K, Kariya R, Pothipan P, Fujikawa S, Pairojkul C, Waraasawapati S, Kuwahara K, Wongkham C, Wongkham S, Okada S. Attenuation of CD47-SIRPα Signal in Cholangiocarcinoma Potentiates Tumor-Associated Macrophage-Mediated Phagocytosis and Suppresses Intrahepatic Metastasis. Transl Oncol 2019;12:217-25. [PMID: 30415063 DOI: 10.1016/j.tranon.2018.10.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
77 Quintavalle C, Burmeister K, Piscuoglio S, Quagliata L, Karamitopoulou E, Sepe R, Fusco A, Terracciano LM, Andersen JB, Pallante P, Matter MS. High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy. Mol Carcinog 2017;56:2146-57. [PMID: 28467612 DOI: 10.1002/mc.22671] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
78 Gingold JA, Zhu D, Lee DF, Kaseb A, Chen J. Genomic Profiling and Metabolic Homeostasis in Primary Liver Cancers. Trends Mol Med. 2018;24:395-411. [PMID: 29530485 DOI: 10.1016/j.molmed.2018.02.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
79 Truong SDA, Tummanatsakun D, Proungvitaya T, Limpaiboon T, Wongwattanakul M, Chua-On D, Roytrakul S, Proungvitaya S. Serum Levels of Cytokine-Induced Apoptosis Inhibitor 1 (CIAPIN1) as a Potential Prognostic Biomarker of Cholangiocarcinoma. Diagnostics (Basel) 2021;11:1054. [PMID: 34201138 DOI: 10.3390/diagnostics11061054] [Reference Citation Analysis]
80 Wu Y, Zhou D, Zhang G, Yi F, Feng L. Preoperative Serum Platelet-Lymphocyte Ratio as a Prognostic Factor in Cholangiocarcinoma Patients after Radical Resection: A Retrospective Analysis of 119 Patients. Gastroenterol Res Pract 2019;2019:8506967. [PMID: 30809257 DOI: 10.1155/2019/8506967] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
81 Yosudjai J, Inpad C, Pothipan P, Saisomboon S, Surangkul D, Phimsen S, Hongsrichan N, Wongkham S, Jirawatnotai S, Roytrakul S, Kaewkong W. Overexpression of AGR2vH, an oncogenic AGR2 spliced transcript, potentiates tumorigenicity and proteomic alterations in cholangiocarcinoma cell. Biosci Biotechnol Biochem 2021;85:2263-73. [PMID: 34494080 DOI: 10.1093/bbb/zbab156] [Reference Citation Analysis]
82 Yugawa K, Itoh S, Iseda N, Kurihara T, Kitamura Y, Toshima T, Harada N, Kohashi K, Baba S, Ishigami K, Oda Y, Yoshizumi T, Mori M. Obesity is a risk factor for intrahepatic cholangiocarcinoma progression associated with alterations of metabolic activity and immune status. Sci Rep 2021;11:5845. [PMID: 33712681 DOI: 10.1038/s41598-021-85186-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
83 Saengboonmee C, Seubwai W, Lert-Itthiporn W, Sanlung T, Wongkham S. Association of Diabetes Mellitus and Cholangiocarcinoma: Update of Evidence and the Effects of Antidiabetic Medication. Can J Diabetes 2021;45:282-90. [PMID: 33218924 DOI: 10.1016/j.jcjd.2020.09.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Navas MC, Glaser S, Dhruv H, Celinski S, Alpini G, Meng F. Hepatitis C Virus Infection and Cholangiocarcinoma: An Insight into Epidemiologic Evidences and Hypothetical Mechanisms of Oncogenesis. Am J Pathol 2019;189:1122-32. [PMID: 30953604 DOI: 10.1016/j.ajpath.2019.01.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
85 Vij M, Puri Y, Rammohan A, G G, Rajalingam R, Kaliamoorthy I, Rela M. Pathological, molecular, and clinical characteristics of cholangiocarcinoma: A comprehensive review. World J Gastrointest Oncol 2022; 14(3): 607-627 [DOI: 10.4251/wjgo.v14.i3.607] [Reference Citation Analysis]
86 Tian Y, Tang B, Wang C, Wang Y, Mao J, Yao Y, Gao Z, Liang R, Ye M, Cai S, Wang L. Operative ubiquitin-specific protease 22 deubiquitination confers a more invasive phenotype to cholangiocarcinoma. Cell Death Dis 2021;12:678. [PMID: 34226501 DOI: 10.1038/s41419-021-03940-0] [Reference Citation Analysis]
87 Bragazzi MC, Ridola L, Safarikia S, Matteo SD, Costantini D, Nevi L, Cardinale V. New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin. Ann Gastroenterol. 2018;31:42-55. [PMID: 29333066 DOI: 10.20524/aog.2017.0209] [Cited by in Crossref: 13] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
88 Xu G, Sun L, Li Y, Xie F, Zhou X, Yang H, Du S, Xu H, Mao Y. The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis. Front Oncol 2019;9:897. [PMID: 31620360 DOI: 10.3389/fonc.2019.00897] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
89 Mammola CL, Vetuschi A, Pannarale L, Sferra R, Mancinelli R. Epidermal growth factor-like domain multiple 7 (EGFL7): Expression and possible effect on biliary epithelium growth in cholangiocarcinoma. Eur J Histochem 2018;62. [PMID: 30504933 DOI: 10.4081/ejh.2018.2971] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
90 Polidoro MA, Mikulak J, Cazzetta V, Lleo A, Mavilio D, Torzilli G, Donadon M. Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells. World J Gastroenterol 2020; 26(33): 4900-4918 [PMID: 32952338 DOI: 10.3748/wjg.v26.i33.4900] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
91 Safarpour AR, Askari H, Ejtehadi F, Azarnezhad A, Raeis-Abdollahi E, Tajbakhsh A, Abazari MF, Tarkesh F, Shamsaeefar A, Niknam R, Sivandzadeh GR, Lankarani KB, Ejtehadi F. Cholangiocarcinoma and liver transplantation: What we know so far? World J Gastrointest Pathophysiol 2021; 12(5): 84-105 [PMID: 34676129 DOI: 10.4291/wjgp.v12.i5.84] [Reference Citation Analysis]
92 Mancinelli R, Cutone A, Rosa L, Lepanto MS, Onori P, Pannarale L, Franchitto A, Gaudio E, Valenti P. Different iron-handling in inflamed small and large cholangiocytes and in small and large-duct type intrahepatic cholangiocarcinoma. Eur J Histochem 2020;64. [PMID: 33131269 DOI: 10.4081/ejh.2020.3156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
93 Zhang R, Puzzoni M, Mariani S, Zheng Y, Liscia N, Guo Y, Donisi C, Liu Y, Impera V, Fang W, Scartozzi M. Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers. Cancer Sci 2021. [PMID: 34534382 DOI: 10.1111/cas.15139] [Reference Citation Analysis]
94 Braconi C, Roessler S, Kruk B, Lammert F, Krawczyk M, Andersen JB. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine? Liver Int 2019;39 Suppl 1:32-42. [PMID: 30829432 DOI: 10.1111/liv.14085] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
95 Lampis A, Carotenuto P, Vlachogiannis G, Cascione L, Hedayat S, Burke R, Clarke P, Bosma E, Simbolo M, Scarpa A, Yu S, Cole R, Smyth E, Mateos JF, Begum R, Hezelova B, Eltahir Z, Wotherspoon A, Fotiadis N, Bali MA, Nepal C, Khan K, Stubbs M, Hahne JC, Gasparini P, Guzzardo V, Croce CM, Eccles S, Fassan M, Cunningham D, Andersen JB, Workman P, Valeri N, Braconi C. MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology. 2018;154:1066-1079.e5. [PMID: 29113809 DOI: 10.1053/j.gastro.2017.10.043] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 9.6] [Reference Citation Analysis]
96 Jiraviriyakul A, Songjang W, Kaewthet P, Tanawatkitichai P, Bayan P, Pongcharoen S. Honokiol-enhanced cytotoxic T lymphocyte activity against cholangiocarcinoma cells mediated by dendritic cells pulsed with damage-associated molecular patterns. World J Gastroenterol 2019; 25(29): 3941-3955 [PMID: 31413529 DOI: 10.3748/wjg.v25.i29.3941] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
97 Merdrignac A, Angenard G, Allain C, Petitjean K, Bergeat D, Bellaud P, Fautrel A, Turlin B, Clément B, Dooley S, Sulpice L, Boudjema K, Coulouarn C. A novel transforming growth factor beta-induced long noncoding RNA promotes an inflammatory microenvironment in human intrahepatic cholangiocarcinoma. Hepatol Commun 2018;2:254-69. [PMID: 29507901 DOI: 10.1002/hep4.1142] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
98 Panettieri E, Maki H, Kim BJ, Kang HC, Cox V, Vega EA, Mizuno T, Pant S, Javle M, Vauthey JN, Kawaguchi Y. Arterial enhancement pattern predicts survival in patients with resectable and unresectable intrahepatic cholangiocarcinoma. Surg Oncol 2021;40:101696. [PMID: 34995974 DOI: 10.1016/j.suronc.2021.101696] [Reference Citation Analysis]
99 Chakrabarti S, Kamgar M, Mahipal A. Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm.Cancers (Basel). 2020;12. [PMID: 32722188 DOI: 10.3390/cancers12082039] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
100 Macias RIR, Monte MJ, Serrano MA, González-Santiago JM, Martín-Arribas I, Simão AL, Castro RE, González-Gallego J, Mauriz JL, Marin JJG. Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. Aging (Albany NY) 2021;13:23416-34. [PMID: 34633987 DOI: 10.18632/aging.203620] [Reference Citation Analysis]
101 Maier CF, Zhu L, Nanduri LK, Kühn D, Kochall S, Thepkaysone ML, William D, Grützmann K, Klink B, Betge J, Weitz J, Rahbari NN, Reißfelder C, Schölch S. Patient-Derived Organoids of Cholangiocarcinoma. Int J Mol Sci 2021;22:8675. [PMID: 34445380 DOI: 10.3390/ijms22168675] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 King G, Javle M. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma. Curr Oncol Rep 2021;23:108. [PMID: 34269915 DOI: 10.1007/s11912-021-01100-3] [Reference Citation Analysis]
103 Chen SY, Huang HY, Lin HP, Fang CY. Piperlongumine induces autophagy in biliary cancer cells via reactive oxygen species-activated Erk signaling pathway. Int J Mol Med 2019;44:1687-96. [PMID: 31485612 DOI: 10.3892/ijmm.2019.4324] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
104 Broutier L, Mastrogiovanni G, Verstegen MM, Francies HE, Gavarró LM, Bradshaw CR, Allen GE, Arnes-Benito R, Sidorova O, Gaspersz MP, Georgakopoulos N, Koo BK, Dietmann S, Davies SE, Praseedom RK, Lieshout R, IJzermans JNM, Wigmore SJ, Saeb-Parsy K, Garnett MJ, van der Laan LJ, Huch M. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med 2017;23:1424-35. [PMID: 29131160 DOI: 10.1038/nm.4438] [Cited by in Crossref: 408] [Cited by in F6Publishing: 391] [Article Influence: 81.6] [Reference Citation Analysis]
105 O'rourke CJ, Munoz-garrido P, Aguayo EL, Andersen JB. Epigenome dysregulation in cholangiocarcinoma. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018;1864:1423-34. [DOI: 10.1016/j.bbadis.2017.06.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
106 Li M, Du M, Cong H, Gu Y, Fang Y, Li J, Gan Y, Tu H, Gu J, Xia Q. Characterization of hepatitis B virus DNA integration patterns in intrahepatic cholangiocarcinoma. Hepatol Res 2021;51:102-15. [PMID: 33037855 DOI: 10.1111/hepr.13580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Thornblade LW, Wong P, Li D, Warner SG, Chang S, Raoof M, Kessler J, Amini A, Lin J, Chung V, Singh G, Fong Y, Melstrom LG. Patterns of Whole Exome Sequencing in Resected Cholangiocarcinoma. Cancers (Basel) 2021;13:4062. [PMID: 34439216 DOI: 10.3390/cancers13164062] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Tusskorn O, Khunluck T, Prawan A, Senggunprai L, Kukongviriyapan V. Mitochondrial division inhibitor-1 potentiates cisplatin-induced apoptosis via the mitochondrial death pathway in cholangiocarcinoma cells. Biomed Pharmacother 2019;111:109-18. [PMID: 30579250 DOI: 10.1016/j.biopha.2018.12.051] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
109 Tian L, Ma J, Ma L, Zheng B, Liu L, Song D, Wang Y, Zhang Z, Gao Q, Song K, Wang X. PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome. World J Surg Oncol. 2020;18:303. [PMID: 33228682 DOI: 10.1186/s12957-020-02082-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
110 Liu YJ, Hounye AH, Wang Z, Liu X, Yi J, Qi M. Identification and Validation of Three Autophagy-Related Long Noncoding RNAs as Prognostic Signature in Cholangiocarcinoma. Front Oncol 2021;11:780601. [PMID: 34926294 DOI: 10.3389/fonc.2021.780601] [Reference Citation Analysis]
111 Sirica AE, Strazzabosco M, Cadamuro M. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Adv Cancer Res 2021;149:321-87. [PMID: 33579427 DOI: 10.1016/bs.acr.2020.10.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
112 Pellino A, Loupakis F, Cadamuro M, Dadduzio V, Fassan M, Guido M, Cillo U, Indraccolo S, Fabris L. Precision medicine in cholangiocarcinoma. Transl Gastroenterol Hepatol 2018;3:40. [PMID: 30148225 DOI: 10.21037/tgh.2018.07.02] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
113 Montal R, Sia D, Montironi C, Leow WQ, Esteban-Fabró R, Pinyol R, Torres-Martin M, Bassaganyas L, Moeini A, Peix J, Cabellos L, Maeda M, Villacorta-Martin C, Tabrizian P, Rodriguez-Carunchio L, Castellano G, Sempoux C, Minguez B, Pawlik TM, Labgaa I, Roberts LR, Sole M, Fiel MI, Thung S, Fuster J, Roayaie S, Villanueva A, Schwartz M, Llovet JM. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol 2020;73:315-27. [PMID: 32173382 DOI: 10.1016/j.jhep.2020.03.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
114 Rizzo A. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors. Medicina (Kaunas) 2021;57:458. [PMID: 34066684 DOI: 10.3390/medicina57050458] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Rizzo A, Brandi G. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review. Cancer Treat Res Commun 2021;27:100354. [PMID: 33756174 DOI: 10.1016/j.ctarc.2021.100354] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
116 Wu L, Merath K, Farooq A, Hyer JM, Tsilimigras DI, Paredes AZ, Mehta R, Sahara K, Shen F, Pawlik TM. Photodynamic therapy may provide a benefit over systemic chemotherapy among non-surgically managed patients with extrahepatic cholangiocarcinoma. J Surg Oncol 2019. [PMID: 31742706 DOI: 10.1002/jso.25773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
117 Judée F, Vaquero J, Guégan S, Fouassier L, Dufour T. Atmospheric pressure plasma jets applied to cancerology: correlating electrical configuration with in vivo toxicity and therapeutic efficiency. J Phys D: Appl Phys 2019;52:245201. [DOI: 10.1088/1361-6463/ab0fbb] [Cited by in Crossref: 10] [Article Influence: 3.3] [Reference Citation Analysis]
118 Macias RIR, Banales JM, Sangro B, Muntané J, Avila MA, Lozano E, Perugorria MJ, Padillo FJ, Bujanda L, Marin JJG. The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis 2018;1864:1468-77. [PMID: 28782657 DOI: 10.1016/j.bbadis.2017.08.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
119 Lee H, Ross JS. The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer. Therap Adv Gastroenterol. 2017;10:507-520. [PMID: 28567120 DOI: 10.1177/1756283x17698090] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
120 Nepal C, O'Rourke CJ, Oliveira DVNP, Taranta A, Shema S, Gautam P, Calderaro J, Barbour A, Raggi C, Wennerberg K, Wang XW, Lautem A, Roberts LR, Andersen JB. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. Hepatology 2018;68:949-63. [PMID: 29278425 DOI: 10.1002/hep.29764] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 11.8] [Reference Citation Analysis]
121 Hill MA, Alexander WB, Guo B, Kato Y, Patra K, O'Dell MR, McCall MN, Whitney-Miller CL, Bardeesy N, Hezel AF. Kras and Tp53 Mutations Cause Cholangiocyte- and Hepatocyte-Derived Cholangiocarcinoma. Cancer Res 2018;78:4445-51. [PMID: 29871934 DOI: 10.1158/0008-5472.CAN-17-1123] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
122 Høgdall D, Lewinska M, Andersen JB. Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma. Trends Cancer 2018;4:239-55. [PMID: 29506673 DOI: 10.1016/j.trecan.2018.01.007] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 10.0] [Reference Citation Analysis]
123 Saffioti F, Mavroeidis VK. Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis. World J Gastrointest Oncol 2021; 13(10): 1336-1366 [PMID: 34721770 DOI: 10.4251/wjgo.v13.i10.1336] [Reference Citation Analysis]
124 Chueakwon P, Jatooratthawichot P, Talabnin K, Ketudat Cairns JR, Talabnin C. Inhibition of Ceramide Glycosylation Enhances Cisplatin Sensitivity in Cholangiocarcinoma by Limiting the Activation of the ERK Signaling Pathway. Life 2022;12:351. [DOI: 10.3390/life12030351] [Reference Citation Analysis]
125 Hall C, Ehrlich L, Venter J, O'Brien A, White T, Zhou T, Dang T, Meng F, Invernizzi P, Bernuzzi F, Alpini G, Lairmore TC, Glaser S. Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth. Cancer Lett 2017;386:179-88. [PMID: 27894959 DOI: 10.1016/j.canlet.2016.11.025] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
126 Krasinskas AM. Cholangiocarcinoma. Surgical Pathology Clinics 2018;11:403-29. [DOI: 10.1016/j.path.2018.02.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
127 Safarikia S, Carpino G, Overi D, Cardinale V, Venere R, Franchitto A, Onori P, Alvaro D, Gaudio E. Distinct EpCAM-Positive Stem Cell Niches Are Engaged in Chronic and Neoplastic Liver Diseases. Front Med (Lausanne) 2020;7:479. [PMID: 32984373 DOI: 10.3389/fmed.2020.00479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
128 Puthdee N, Sriswasdi S, Pisitkun T, Ratanasirintrawoot S, Israsena N, Tangkijvanich P. The LIN28B/TGF-β/TGFBI feedback loop promotes cell migration and tumour initiation potential in cholangiocarcinoma. Cancer Gene Ther 2021. [PMID: 34548635 DOI: 10.1038/s41417-021-00387-5] [Reference Citation Analysis]
129 Bednarsch J, Tan X, Czigany Z, Liu D, Lang SA, Sivakumar S, Kather JN, Appinger S, Rosin M, Boroojerdi S, Dahl E, Gaisa NT, den Dulk M, Coolsen M, Ulmer TF, Neumann UP, Heij LR. The Presence of Small Nerve Fibers in the Tumor Microenvironment as Predictive Biomarker of Oncological Outcome Following Partial Hepatectomy for Intrahepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:3661. [PMID: 34359564 DOI: 10.3390/cancers13153661] [Reference Citation Analysis]
130 Wu HJ, Chu PY. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications. Int J Mol Sci 2019;20:E4154. [PMID: 31450710 DOI: 10.3390/ijms20174154] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
131 Zhang DY, Ma SS, Sun WL, Lv XCH, Lu Z. KIF4A as a novel prognostic biomarker in cholangiocarcinoma. Medicine (Baltimore) 2021;100:e26130. [PMID: 34032761 DOI: 10.1097/MD.0000000000026130] [Reference Citation Analysis]
132 Forner A, Vidili G, Rengo M, Bujanda L, Ponz‐sarvisé M, Lamarca A. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int 2019;39:98-107. [DOI: 10.1111/liv.14086] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 17.3] [Reference Citation Analysis]
133 Di Matteo S, Nevi L, Overi D, Landolina N, Faccioli J, Giulitti F, Napoletano C, Oddi A, Marziani AM, Costantini D, De Rose AM, Melandro F, Bragazzi MC, Grazi GL, Berloco PB, Giuliante F, Donato G, Moretta L, Carpino G, Cardinale V, Gaudio E, Alvaro D. Metformin exerts anti-cancerogenic effects and reverses epithelial-to-mesenchymal transition trait in primary human intrahepatic cholangiocarcinoma cells. Sci Rep 2021;11:2557. [PMID: 33510179 DOI: 10.1038/s41598-021-81172-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
134 Ioffe D, Phull P, Dotan E. Optimal Management of Patients with Advanced or Metastatic Cholangiocarcinoma: An Evidence-Based Review. Cancer Manag Res 2021;13:8085-98. [PMID: 34737637 DOI: 10.2147/CMAR.S276104] [Reference Citation Analysis]
135 Palmieri LJ, Lavolé J, Dermine S, Brezault C, Dhooge M, Barré A, Chaussade S, Coriat R. The choice for the optimal therapy in advanced biliary tract cancers: Chemotherapy, targeted therapies or immunotherapy. Pharmacol Ther 2020;210:107517. [PMID: 32109491 DOI: 10.1016/j.pharmthera.2020.107517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
136 Crispo F, Pietrafesa M, Condelli V, Maddalena F, Bruno G, Piscazzi A, Sgambato A, Esposito F, Landriscina M. IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment-Current State and Future Perspectives. Molecules 2020;25:E3754. [PMID: 32824685 DOI: 10.3390/molecules25163754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
137 Maphanao P, Thanan R, Loilome W, Chio-Srichan S, Wongwattanakul M, Sakonsinsiri C. Synchrotron FTIR microspectroscopy revealed apoptosis-induced biomolecular changes of cholangiocarcinoma cells treated with ursolic acid. Biochim Biophys Acta Gen Subj 2020;1864:129708. [PMID: 32810561 DOI: 10.1016/j.bbagen.2020.129708] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
138 Díaz-González Á, Vilana R, Bianchi L, García-Criado Á, Rimola J, Rodríguez de Lope C, Ferrer J, Ayuso C, Da Fonseca LG, Reig M, Forner A. Thermal Ablation for Intrahepatic Cholangiocarcinoma in Cirrhosis: Safety and Efficacy in Non-Surgical Patients. J Vasc Interv Radiol 2020;31:710-9. [PMID: 31685360 DOI: 10.1016/j.jvir.2019.06.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
139 Abdelrahim M, Al-rawi H, Esmail A, Xu J, Umoru G, Ibnshamsah F, Abudayyeh A, Victor D, Saharia A, Mcmillan R, Al Najjar E, Bugazia D, Al-rawi M, Ghobrial RM. Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series. Current Oncology 2022;29:3585-94. [DOI: 10.3390/curroncol29050290] [Reference Citation Analysis]
140 Namjan A, Techasen A, Loilome W, Sa-Ngaimwibool P, Jusakul A. ARID1A alterations and their clinical significance in cholangiocarcinoma. PeerJ 2020;8:e10464. [PMID: 33344089 DOI: 10.7717/peerj.10464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
141 Li W, Ma Z, Fu X, Hao Z, Shang H, Shi J, Lei M, Xu M, Ning S, Hua X. Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report. Ann Transl Med 2021;9:1487. [PMID: 34734039 DOI: 10.21037/atm-21-3681] [Reference Citation Analysis]
142 Cardinale V. Classifications and misclassification in cholangiocarcinoma. Liver Int. 2019;39:260-262. [PMID: 30694026 DOI: 10.1111/liv.13998] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
143 Kriegsmann M, Roessler S, Kriegsmann K, Renner M, Longuespée R, Albrecht T, Loeffler M, Singer S, Mehrabi A, Vogel MN, Pathil A, Köhler B, Springfeld C, Rupp C, Weiss KH, Goeppert B. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies. BMC Cancer 2019;19:72. [PMID: 30646854 DOI: 10.1186/s12885-018-5254-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
144 Rizzo A, Tavolari S, Ricci AD, Frega G, Palloni A, Relli V, Salati M, Fenocchio E, Massa A, Aglietta M, Brandi G. Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures. Cancers (Basel) 2020;12:E3256. [PMID: 33158162 DOI: 10.3390/cancers12113256] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
145 Cardinale V, Carpino G. Multilevel heterogeneity of biliary tract cancers may affect the modelling of prognosis. Liver Int 2017;37:1773-5. [PMID: 29149490 DOI: 10.1111/liv.13565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
146 Wang Y, Yu H, Xie X, Deng T, Ye L, Wu L, Ding X, Yang Z, Zhu Q, Li J, Zheng Y, Yu Z, Chen G. Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway. Oncogene 2021;40:4324-37. [PMID: 34079085 DOI: 10.1038/s41388-021-01844-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Büttner S, Galjart B, Beumer BR, van Vugt JL, van Eijck CH, Polak WG, de Jonge J, Homs MY, van Driel LM, Pawlik TM, Steyerberg EW, Ijzermans JN, Groot Koerkamp B. Quality and performance of validated prognostic models for survival after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. HPB 2021;23:25-36. [DOI: 10.1016/j.hpb.2020.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Vaquero J, Lobe C, Fouassier L. Unveiling resistance mechanisms to EGFR inhibitors in cholangiocarcinoma. Oncotarget 2018;9:37274-5. [PMID: 30647862 DOI: 10.18632/oncotarget.26403] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
149 Sritana N, Suriyo T, Kanitwithayanun J, Songvasin BH, Thiantanawat A, Satayavivad J. Glyphosate induces growth of estrogen receptor alpha positive cholangiocarcinoma cells via non-genomic estrogen receptor/ERK1/2 signaling pathway. Food and Chemical Toxicology 2018;118:595-607. [DOI: 10.1016/j.fct.2018.06.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
150 Jaidee R, Kongpetch S, Senggunprai L, Prawan A, Kukongviriyapan U, Kukongviriyapan V. Phenformin inhibits proliferation, invasion, and angiogenesis of cholangiocarcinoma cells via AMPK-mTOR and HIF-1A pathways. Naunyn Schmiedebergs Arch Pharmacol 2020;393:1681-90. [PMID: 32383028 DOI: 10.1007/s00210-020-01885-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
151 Daya M, Loilome W, Techasen A, Thanee M, Sa-Ngiamwibool P, Titapun A, Yongvanit P, Namwat N. Progranulin modulates cholangiocarcinoma cell proliferation, apoptosis, and motility via the PI3K/pAkt pathway. Onco Targets Ther 2018;11:395-408. [PMID: 29403285 DOI: 10.2147/OTT.S155511] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
152 Rizzo A, Brandi G. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!". Cancer Treat Res Commun 2021;27:100335. [PMID: 33592561 DOI: 10.1016/j.ctarc.2021.100335] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
153 Byrling J, Sasor A, Nilsson J, Said Hilmersson K, Andersson R, Andersson B. Expression of fibroblast activation protein and the clinicopathological relevance in distal cholangiocarcinoma. Scand J Gastroenterol 2020;55:82-9. [PMID: 31917931 DOI: 10.1080/00365521.2019.1708449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
154 Marzouk O, Lakshmaiah S, Anjarwalla S. Perihilar clear cell cholangiocarcinoma: an often-diagnostic challenge. BMJ Case Rep 2020;13:e237683. [PMID: 33370986 DOI: 10.1136/bcr-2020-237683] [Reference Citation Analysis]
155 Yang R, Wang D, Han S, Gu Y, Li Z, Deng L, Yin A, Gao Y, Li X, Yu Y, Wang X. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs. Int J Biol Sci 2022;18:43-64. [PMID: 34975317 DOI: 10.7150/ijbs.62602] [Reference Citation Analysis]
156 Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int. 2019;39 Suppl 1:19-31. [PMID: 30851228 DOI: 10.1111/liv.14095] [Cited by in Crossref: 104] [Cited by in F6Publishing: 105] [Article Influence: 34.7] [Reference Citation Analysis]
157 Mayr C, Ocker M, Ritter M, Pichler M, Neureiter D, Kiesslich T. Biliary tract cancer stem cells - translational options and challenges. World J Gastroenterol 2017; 23(14): 2470-2482 [PMID: 28465631 DOI: 10.3748/wjg.v23.i14.2470] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
158 Simile MM, Bagella P, Vidili G, Spanu A, Manetti R, Seddaiu MA, Babudieri S, Madeddu G, Serra PA, Altana M, Paliogiannis P. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials. Medicina (Kaunas) 2019;55:E42. [PMID: 30743998 DOI: 10.3390/medicina55020042] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
159 Sato K, Baiocchi L, Kennedy L, Zhang W, Ekser B, Glaser S, Francis H, Alpini G. Current Advances in Basic and Translational Research of Cholangiocarcinoma. Cancers (Basel) 2021;13:3307. [PMID: 34282753 DOI: 10.3390/cancers13133307] [Reference Citation Analysis]
160 Peng T, Li Z, Li D, Wang S. MACC1 promotes angiogenesis in cholangiocarcinoma by upregulating VEGFA. Onco Targets Ther 2019;12:1893-903. [PMID: 30881041 DOI: 10.2147/OTT.S197319] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
161 Vaquero J, Judée F, Vallette M, Decauchy H, Arbelaiz A, Aoudjehane L, Scatton O, Gonzalez-Sanchez E, Merabtene F, Augustin J, Housset C, Dufour T, Fouassier L. Cold-Atmospheric Plasma Induces Tumor Cell Death in Preclinical In Vivo and In Vitro Models of Human Cholangiocarcinoma. Cancers (Basel) 2020;12:E1280. [PMID: 32438553 DOI: 10.3390/cancers12051280] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
162 Guo LQ, Sun HW, Zhang CY, Feng Y, Teng XL, Qu YK. Efficacy of fluoxetine for anorexia nervosa caused by chemotherapy in patients with cholangiocarcinoma. Medicine (Baltimore) 2019;98:e15945. [PMID: 31192931 DOI: 10.1097/MD.0000000000015945] [Reference Citation Analysis]
163 Ning S, Ma S, Saleh AQ, Guo L, Zhao Z, Chen Y. SHMT2 Overexpression Predicts Poor Prognosis in Intrahepatic Cholangiocarcinoma. Gastroenterol Res Pract 2018;2018:4369253. [PMID: 30228815 DOI: 10.1155/2018/4369253] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
164 Wheatley RC, Kilgour E, Jacobs T, Lamarca A, Hubner RA, Valle JW, McNamara MG. Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy. Br J Cancer 2021. [PMID: 34663949 DOI: 10.1038/s41416-021-01583-8] [Reference Citation Analysis]
165 Rahnemai-Azar AA, Weisbrod AB, Dillhoff M, Schmidt C, Pawlik TM. Intrahepatic cholangiocarcinoma: current management and emerging therapies. Expert Rev Gastroenterol Hepatol 2017;11:439-49. [PMID: 28317403 DOI: 10.1080/17474124.2017.1309290] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
166 Byrling J, Andersson R, Sasor A, Lindell G, Ansari D, Nilsson J, Andersson B. Outcome and evaluation of prognostic factors after pancreaticoduodenectomy for distal cholangiocarcinoma. Ann Gastroenterol 2017;30:571-7. [PMID: 28845114 DOI: 10.20524/aog.2017.0169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
167 Raggi C, Taddei ML, Sacco E, Navari N, Correnti M, Piombanti B, Pastore M, Campani C, Pranzini E, Iorio J, Lori G, Lottini T, Peano C, Cibella J, Lewinska M, Andersen JB, di Tommaso L, Viganò L, Di Maira G, Madiai S, Ramazzotti M, Orlandi I, Arcangeli A, Chiarugi P, Marra F. Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma. J Hepatol 2021;74:1373-85. [PMID: 33484774 DOI: 10.1016/j.jhep.2020.12.031] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
168 Rompianesi G, Di Martino M, Gordon-Weeks A, Montalti R, Troisi R. Liquid biopsy in cholangiocarcinoma: Current status and future perspectives. World J Gastrointest Oncol 2021;13:332-50. [PMID: 34040697 DOI: 10.4251/wjgo.v13.i5.332] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
169 Koessler T, Alsina M, Arnold D, Ben-Aharon I, Collienne M, Lutz MP, Neuzillet C, Obermannova R, Peeters M, Sclafani F, Smyth E, Valle JW, Wagner AD, Wyrwicz L, Fontana E, Moehler M. ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective. ESMO Open 2022;7:100392. [PMID: 35180656 DOI: 10.1016/j.esmoop.2022.100392] [Reference Citation Analysis]
170 Merino-Azpitarte M, Lozano E, Perugorria MJ, Esparza-Baquer A, Erice O, Santos-Laso Á, O'Rourke CJ, Andersen JB, Jiménez-Agüero R, Lacasta A, D'Amato M, Briz Ó, Jalan-Sakrikar N, Huebert RC, Thelen KM, Gradilone SA, Aransay AM, Lavín JL, Fernández-Barrena MG, Matheu A, Marzioni M, Gores GJ, Bujanda L, Marin JJG, Banales JM. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. J Hepatol 2017;67:72-83. [PMID: 28237397 DOI: 10.1016/j.jhep.2017.02.017] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 9.4] [Reference Citation Analysis]
171 Lee PC, Hendifar A, Osipov A, Cho M, Li D, Gong J. Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations. Cancers (Basel) 2021;13:1706. [PMID: 33916849 DOI: 10.3390/cancers13071706] [Reference Citation Analysis]
172 Tomacha J, Dokduang H, Padthaisong S, Namwat N, Klanrit P, Phetcharaburanin J, Wangwiwatsin A, Khampitak T, Koonmee S, Titapun A, Jarearnrat A, Khuntikeo N, Loilome W. Targeting Fatty Acid Synthase Modulates Metabolic Pathways and Inhibits Cholangiocarcinoma Cell Progression. Front Pharmacol 2021;12:696961. [PMID: 34421595 DOI: 10.3389/fphar.2021.696961] [Reference Citation Analysis]
173 Lomphithak T, Choksi S, Mutirangura A, Tohtong R, Tencomnao T, Usubuchi H, Unno M, Sasano H, Jitkaew S. Receptor-interacting protein kinase 1 is a key mediator in TLR3 ligand and Smac mimetic-induced cell death and suppresses TLR3 ligand-promoted invasion in cholangiocarcinoma. Cell Commun Signal 2020;18:161. [PMID: 33036630 DOI: 10.1186/s12964-020-00661-3] [Reference Citation Analysis]
174 Cai W, Yuan Y, Ge W, Fan Y, Liu X, Wu D, Hu H. EGFR Target Therapy Combined with Gemox for Advanced Biliary Tract Cancers: a Meta-analysis based on RCTs. J Cancer 2018;9:1476-85. [PMID: 29721058 DOI: 10.7150/jca.23290] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
175 Abbasi A, Rahnemai-azar AA, Ronnekleiv-kelly SM, Abbott DE, Weber SM. Clinical Presentation and Diagnosis. In: Pawlik TM, Cloyd JM, Dillhoff M, editors. Intrahepatic Cholangiocarcinoma. Cham: Springer International Publishing; 2019. pp. 11-20. [DOI: 10.1007/978-3-030-22258-1_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
176 Lapitz A, Arbelaiz A, Olaizola P, Aranburu A, Bujanda L, Perugorria MJ, Banales JM. Extracellular Vesicles in Hepatobiliary Malignancies. Front Immunol 2018;9:2270. [PMID: 30369925 DOI: 10.3389/fimmu.2018.02270] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
177 O'Rourke CJ, Lafuente-Barquero J, Andersen JB. Epigenome Remodeling in Cholangiocarcinoma. Trends Cancer. 2019;5:335-350. [PMID: 31208696 DOI: 10.1016/j.trecan.2019.05.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
178 Roy S, Banerjee P, Ekser B, Bayless K, Zawieja D, Alpini G, Glaser SS, Chakraborty S. Targeting Lymphangiogenesis and Lymph Node Metastasis in Liver Cancer. Am J Pathol 2021;191:2052-63. [PMID: 34509441 DOI: 10.1016/j.ajpath.2021.08.011] [Reference Citation Analysis]
179 Zhao K, Li X, Shi Y, Lu Y, Qiu P, Deng Z, Yao W, Wang J. Exosomes in the tumor microenvironment of cholangiocarcinoma: current status and future perspectives. J Transl Med 2022;20. [DOI: 10.1186/s12967-022-03294-x] [Reference Citation Analysis]
180 Massani M, Stecca T, Pauletti B, Marte G, Ruffolo C, Bonariol L, Bassi N. Intrahepatic Cholangiocarcinoma. In: Abdeldayem H, editor. Topics in the Surgery of the Biliary Tree. InTech; 2018. [DOI: 10.5772/intechopen.75516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
181 Tang Z, Yang Y, Meng W, Li X. Best option for preoperative biliary drainage in Klatskin tumor: A systematic review and meta-analysis. Medicine (Baltimore). 2017;96:e8372. [PMID: 29069029 DOI: 10.1097/md.0000000000008372] [Cited by in Crossref: 32] [Cited by in F6Publishing: 8] [Article Influence: 6.4] [Reference Citation Analysis]
182 Saikawa S, Kaji K, Nishimura N, Seki K, Sato S, Nakanishi K, Kitagawa K, Kawaratani H, Kitade M, Moriya K, Namisaki T, Mitoro A, Yoshiji H. Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein. Cancer Letters 2018;434:120-9. [DOI: 10.1016/j.canlet.2018.07.021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
183 Pericleous M, Khan SA. Epidemiology of HPB malignancy in the elderly. European Journal of Surgical Oncology 2021;47:503-13. [DOI: 10.1016/j.ejso.2020.03.222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
184 Rizzo A, Brandi G. Novel Targeted Therapies for Advanced Cholangiocarcinoma. Medicina (Kaunas) 2021;57:212. [PMID: 33652960 DOI: 10.3390/medicina57030212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
185 He Y, Liu C, Song P, Pang Z, Mo Z, Huang C, Yan T, Sun M, Fa X. Investigation of miRNA- and lncRNA-mediated competing endogenous RNA network in cholangiocarcinoma. Oncol Lett 2019;18:5283-93. [PMID: 31612038 DOI: 10.3892/ol.2019.10852] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
186 Zhang L, Guo W, Yu J, Li C, Li M, Chai D, Wang W, Deng W. Receptor-interacting protein in malignant digestive neoplasms. J Cancer 2021;12:4362-71. [PMID: 34093836 DOI: 10.7150/jca.57076] [Reference Citation Analysis]
187 Pang X, Wan L, Yang J, Bai P, Zhang J, Chen X, Yan X, Ma B. Steroidal saponins from Trillium tschonoskii rhizome repress cancer stemness and proliferation of intrahepatic cholangiocarcinoma. Bioorganic Chemistry 2022. [DOI: 10.1016/j.bioorg.2022.105679] [Reference Citation Analysis]
188 Balasubramanian B, Venkatraman S, Myint KZ, Janvilisri T, Wongprasert K, Kumkate S, Bates DO, Tohtong R. Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma. Pharmaceuticals (Basel) 2021;14:51. [PMID: 33440754 DOI: 10.3390/ph14010051] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
189 Hou P, Kang Y, Luo J. Hypoxia-mediated miR-212-3p downregulation enhances progression of intrahepatic cholangiocarcinoma through upregulation of Rab1a. Cancer Biol Ther 2018;19:984-93. [PMID: 29672195 DOI: 10.1080/15384047.2018.1456608] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
190 de Moura DTH, Ryou M, de Moura EGH, Ribeiro IB, Bernardo WM, Thompson CC. Endoscopic Ultrasound-Guided Fine Needle Aspiration and Endoscopic Retrograde Cholangiopancreatography-Based Tissue Sampling in Suspected Malignant Biliary Strictures: A Meta-Analysis of Same-Session Procedures. Clin Endosc. 2020;53:417-428. [PMID: 31684700 DOI: 10.5946/ce.2019.053] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
191 Ghidini M, Ramai D, Facciorusso A, Singh J, Tai W, Rijavec E, Galassi B, Grossi F, Indini A. Metabolic disorders and the risk of cholangiocarcinoma. Expert Rev Gastroenterol Hepatol 2021;15:999-1007. [PMID: 34423721 DOI: 10.1080/17474124.2021.1946393] [Reference Citation Analysis]
192 Kodali S, Shetty A, Shekhar S, Victor DW, Ghobrial RM. Management of Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2368. [PMID: 34072277 DOI: 10.3390/jcm10112368] [Reference Citation Analysis]
193 Chen X, Qin S, Gu S, Ren Z, Chen Z, Xiong J, Liu Y, Meng Z, Zhang X, Wang L, Zhang X, Zou J. Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial. Int J Cancer 2021. [PMID: 34309846 DOI: 10.1002/ijc.33751] [Reference Citation Analysis]
194 Li L, Qian M, Chen IH, Finkelstein D, Onar-Thomas A, Johnson M, Calabrese C, Bahrami A, López-Terrada DH, Yang JJ, Tao WA, Zhu L. Acquisition of Cholangiocarcinoma Traits during Advanced Hepatocellular Carcinoma Development in Mice. Am J Pathol 2018;188:656-71. [PMID: 29248454 DOI: 10.1016/j.ajpath.2017.11.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
195 Goeppert B, Roessler S, Renner M, Loeffler M, Singer S, Rausch M, Albrecht T, Mehrabi A, Vogel MN, Pathil A, Czink E, Köhler B, Springfeld C, Rupp C, Weiss KH, Schirmacher P, von Knebel Doeberitz M, Kloor M. Low frequency of mismatch repair deficiency in gallbladder cancer. Diagn Pathol 2019;14:36. [PMID: 31068195 DOI: 10.1186/s13000-019-0813-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
196 Hwang JP, Moon JH, Kim HK, Lee MH, Lim CH, Park SB, Yoon JK, Park JM. Prognostic value of metabolic parameters measured by pretreatment dual-time-point 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with intrahepatic or perihilar cholangiocarcinoma: A STROBE study. Medicine (Baltimore) 2021;100:e26015. [PMID: 34032720 DOI: 10.1097/MD.0000000000026015] [Reference Citation Analysis]
197 Perugorria MJ, Olaizola P, Labiano I, Esparza-Baquer A, Marzioni M, Marin JJG, Bujanda L, Banales JM. Wnt-β-catenin signalling in liver development, health and disease. Nat Rev Gastroenterol Hepatol 2019;16:121-36. [PMID: 30451972 DOI: 10.1038/s41575-018-0075-9] [Cited by in Crossref: 105] [Cited by in F6Publishing: 112] [Article Influence: 35.0] [Reference Citation Analysis]
198 Zhang Y, Sun J, Song Y, Gao P, Wang X, Chen M, Li Y, Wu Z. Roles of fusion genes in digestive system cancers: dawn for cancer precision therapy. Crit Rev Oncol Hematol 2022;:103622. [PMID: 35124200 DOI: 10.1016/j.critrevonc.2022.103622] [Reference Citation Analysis]
199 Sripa B, Suwannatrai AT, Sayasone S, Do DT, Khieu V, Yang Y. Current status of human liver fluke infections in the Greater Mekong Subregion. Acta Trop 2021;224:106133. [PMID: 34509453 DOI: 10.1016/j.actatropica.2021.106133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Zhang X, Yang Z, Shi Z, Zhu Z, Li C, Du Z, Zhang Y, Wang Z, Jiao Z, Tian X, Zhang J, Zhai W, Kan Q. Analysis of bile acid profile in plasma to differentiate cholangiocarcinoma from benign biliary diseases and healthy controls. J Steroid Biochem Mol Biol. 2021;205:105775. [PMID: 33130021 DOI: 10.1016/j.jsbmb.2020.105775] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
201 Fouassier L, Marzioni M, Afonso MB, Dooley S, Gaston K, Giannelli G, Rodrigues CMP, Lozano E, Mancarella S, Segatto O, Vaquero J, Marin JJG, Coulouarn C. Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance. Liver Int. 2019;39 Suppl 1:43-62. [PMID: 30903728 DOI: 10.1111/liv.14102] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
202 Olaizola P, Lee-law P, Arbelaiz A, Lapitz A, Perugorria M, Bujanda L, Banales J. MicroRNAs and extracellular vesicles in cholangiopathies. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018;1864:1293-307. [DOI: 10.1016/j.bbadis.2017.06.026] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
203 Rao L, Ma N, Liu Y, Du L, Qu B. Correlation Between Adjuvant Chemotherapy Regimen, Recurrence Pattern and Prognosis of Cholangiocarcinoma After Radical Surgery. Front Oncol 2022;12:695228. [DOI: 10.3389/fonc.2022.695228] [Reference Citation Analysis]
204 Krishna M. Pathology of Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma. Clin Liver Dis (Hoboken) 2021;17:255-60. [PMID: 33968385 DOI: 10.1002/cld.1047] [Reference Citation Analysis]
205 Suwannatrai AT, Thinkhamrop K, Clements ACA, Kelly M, Suwannatrai K, Thinkhamrop B, Khuntikeo N, Gray DJ, Wangdi K. Bayesian spatial analysis of cholangiocarcinoma in Northeast Thailand. Sci Rep 2019;9:14263. [PMID: 31582774 DOI: 10.1038/s41598-019-50476-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
206 Alonso-Peña M, Espinosa-Escudero RA, Soto-Muñiz M, Sanchon-Sanchez P, Sanchez-Martin A, Marin JJ. Role of transportome in the pharmacogenomics of hepatocellular carcinoma and hepatobiliary cancer. Pharmacogenomics 2019;20:957-70. [PMID: 31486734 DOI: 10.2217/pgs-2019-0033] [Reference Citation Analysis]
207 Rizzo A, Ricci AD, Brandi G. Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand? Expert Review of Precision Medicine and Drug Development 2021;6:217-24. [DOI: 10.1080/23808993.2021.1915126] [Reference Citation Analysis]
208 Hochnadel I, Kossatz-Boehlert U, Jedicke N, Lenzen H, Manns MP, Yevsa T. Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. Hum Vaccin Immunother. 2017;13:2931-2952. [PMID: 29112462 DOI: 10.1080/21645515.2017.1359362] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
209 Kamsa-ard S, Kamsa-ard S, Luvira V, Suwanrungruang K, Vatanasapt P, Wiangnon S. Risk Factors for Cholangiocarcinoma in Thailand: A Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev 2018;19:605-14. [PMID: 29579789 DOI: 10.22034/APJCP.2018.19.3.605] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
210 Sahu R, Sharma P, Kumar A. An Insight into Cholangiocarcinoma and Recent Advances in its Treatment. J Gastrointest Cancer 2022. [PMID: 35023010 DOI: 10.1007/s12029-021-00728-5] [Reference Citation Analysis]
211 Mocan LP, Ilieș M, Melincovici CS, Spârchez M, Crăciun R, Nenu I, Horhat A, Tefas C, Spârchez Z, Iuga CA, Mocan T, Mihu CM. Novel approaches in search for biomarkers of cholangiocarcinoma. World J Gastroenterol 2022; 28(15): 1508-1525 [DOI: 10.3748/wjg.v28.i15.1508] [Reference Citation Analysis]
212 Inoue M, Hakoda K, Sawada H, Hotta R, Ohmori I, Miyamoto K, Toyota K, Sadamoto S, Takahashi T. Locally advanced gallbladder cancer treated with effective chemotherapy and subsequent curative resection: a case report. J Med Case Rep 2022;16:30. [PMID: 35039070 DOI: 10.1186/s13256-021-03248-9] [Reference Citation Analysis]
213 Gentilini A, Caligiuri A, Raggi C, Rombouts K, Pinzani M, Lori G, Correnti M, Invernizzi P, Rovida E, Navari N, Di Matteo S, Alvaro D, Banales JM, Rodrigues P, Raschioni C, Donadon M, Di Tommaso L, Marra F. CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cells. Biochim Biophys Acta Mol Basis Dis. 2019;1865:2246-2256. [PMID: 31059778 DOI: 10.1016/j.bbadis.2019.04.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
214 Rizzo A, Ricci AD, Brandi G. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. Cancer Treat Res Commun 2021;27:100337. [PMID: 33611090 DOI: 10.1016/j.ctarc.2021.100337] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
215 Arunsan P, Chaidee A, Cochran CJ, Mann VH, Tanno T, Kumkhaek C, Smout MJ, Karinshak SE, Rodpai R, Sotillo J, Loukas A, Laha T, Brindley PJ, Ittiprasert W. Liver fluke granulin promotes extracellular vesicle-mediated crosstalk and cellular microenvironment conducive to cholangiocarcinoma. Neoplasia 2020;22:203-16. [PMID: 32244128 DOI: 10.1016/j.neo.2020.02.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
216 Bergeat D, Turrini O, Courtin-tanguy L, Truant S, Darnis B, Delpero JR, Mabrut J, Regenet N, Sulpice L. Impact of adjuvant chemotherapy after pancreaticoduodenectomy for distal cholangiocarcinoma: a propensity score analysis from a French multicentric cohort. Langenbecks Arch Surg 2018;403:701-9. [DOI: 10.1007/s00423-018-1702-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
217 Yohanathan L, Croome KP, Traynor M, Puig CA, Mara KC, Cleary SP, Nagorney DM. Significance of proximal ductal margin status after resection of hilar cholangiocarcinoma. HPB (Oxford) 2021;23:109-17. [PMID: 32593583 DOI: 10.1016/j.hpb.2020.05.002] [Reference Citation Analysis]
218 Saengboonmee C, Sawanyawisuth K, Chamgramol Y, Wongkham S. Prognostic biomarkers for cholangiocarcinoma and their clinical implications. Expert Rev Anticancer Ther 2018;18:579-92. [PMID: 29676221 DOI: 10.1080/14737140.2018.1467760] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
219 Chatchawal P, Wongwattanakul M, Tippayawat P, Jearanaikoon N, Jumniansong A, Boonmars T, Jearanaikoon P, Wood BR. Monitoring the Progression of Liver Fluke-Induced Cholangiocarcinoma in a Hamster Model Using Synchrotron FTIR Microspectroscopy and Focal Plane Array Infrared Imaging. Anal Chem 2020;92:15361-9. [PMID: 33170647 DOI: 10.1021/acs.analchem.0c02656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
220 Ghurburrun E, Borbath I, Lemaigre FP, Jacquemin P. Liver and Pancreas: Do Similar Embryonic Development and Tissue Organization Lead to Similar Mechanisms of Tumorigenesis? Gene Expr 2018;18:149-55. [PMID: 29580319 DOI: 10.3727/105221618X15216414278706] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
221 Amer A, Wilson CH, Manas DM. Liver transplantation for unresectable malignancies: Beyond hepatocellular carcinoma. Eur J Surg Oncol 2019;45:2268-78. [PMID: 31387755 DOI: 10.1016/j.ejso.2019.07.024] [Reference Citation Analysis]
222 Alsaleh M, Leftley Z, O'Connor T, Hughes T, Barbera TA, Koomson LK, Zabron A, Reeves H, Cramp M, Ryder SD, Greer S, Prince M, Sithithaworn P, Khuntikeo N, Loilome W, Yongvanit P, Cox IJ, Williams R, Wadsworth CA, Holmes E, Nash K, Andrews R, Taylor-Robinson SD. Mapping of population disparities in the cholangiocarcinoma urinary metabolome. Sci Rep 2021;11:21286. [PMID: 34711878 DOI: 10.1038/s41598-021-00530-0] [Reference Citation Analysis]
223 Kovshirina YV, Fedorova OS, Vtorushin SV, Kovshirina AE, Ivanov SD, Chizhikov AV, Onishchenko SV, Ogorodova LM, Odermatt P. Case Report: Two Cases of Cholangiocarcinoma in Patients with Opisthorchis felineus Infection in Western Siberia, Russian Federation. Am J Trop Med Hyg 2019;100:599-603. [PMID: 30594265 DOI: 10.4269/ajtmh.18-0652] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
224 Labib PL, Davidson BR, Sharma RA, Pereira SP. Locoregional therapies in cholangiocarcinoma. Hepat Oncol 2017;4:99-109. [PMID: 29367874 DOI: 10.2217/hep-2017-0014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
225 Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer.Lancet. 2021;397:428-444. [PMID: 33516341 DOI: 10.1016/S0140-6736(21)00153-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 23.0] [Reference Citation Analysis]
226 Lin J, Cao Y, Yang X, Li G, Shi Y, Wang D, Long J, Song Y, Mao J, Xie F, Bai Y, Zhang L, Yang X, Wan X, Wang A, Guan M, Zhao L, Hu K, Pan J, Huo L, Lu X, Mao Y, Sang X, Zhang H, Wang K, Wang X, Zhao H. Mutational spectrum and precision oncology for biliary tract carcinoma. Theranostics 2021;11:4585-98. [PMID: 33754015 DOI: 10.7150/thno.56539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
227 Ma W, Han C, Zhang J, Song K, Chen W, Kwon H, Wu T. The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis Through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway. Hepatology 2020;72:1283-97. [PMID: 31990985 DOI: 10.1002/hep.31141] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
228 Tamaoka K, Tanemura M, Furukawa K, Mikamori M, Saito T, Ohtsuka M, Suzuki Y, Tei M, Kishi K, Yasuoka H, Tsujimoto M, Akamatsu H. Primary Intrahepatic Squamous Cell Carcinoma with Histological Collision of Adenocarcinoma and Squamous Cell Carcinoma: A Case Report. Am J Case Rep 2018;19:1184-91. [PMID: 30287803 DOI: 10.12659/AJCR.910676] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
229 Yao J, Liang X, Liu Y, Li S, Zheng M. Trends in Incidence and Prognostic Factors of Two Subtypes of Primary Liver Cancers: A Surveillance, Epidemiology, and End Results-Based Population Study. Cancer Control 2022;29:10732748211051548. [PMID: 35147456 DOI: 10.1177/10732748211051548] [Reference Citation Analysis]
230 Indramanee S, Sawanyawisuth K, Silsirivanit A, Dana P, Phoomak C, Kariya R, Klinhom-On N, Sorin S, Wongkham C, Okada S, Wongkham S. Terminal fucose mediates progression of human cholangiocarcinoma through EGF/EGFR activation and the Akt/Erk signaling pathway. Sci Rep 2019;9:17266. [PMID: 31754244 DOI: 10.1038/s41598-019-53601-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
231 Kirstein MM, Vogel A. Epidemiology and Risk Factors of Cholangiocarcinoma. Visc Med. 2016;32:395-400. [PMID: 28229073 DOI: 10.1159/000453013] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 10.5] [Reference Citation Analysis]
232 Rizzato M, Brignola S, Munari G, Gatti M, Dadduzio V, Borga C, Bergamo F, Pellino A, Angerilli V, Mescoli C, Guido M, Rearden J, Gringeri E, Cillo U, Dei Tos AP, Zagonel V, Loupakis F, Lonardi S, Fassan M. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study. Eur J Cancer 2022;166:165-75. [PMID: 35303508 DOI: 10.1016/j.ejca.2022.02.013] [Reference Citation Analysis]
233 He X, Zhu Y, Wang Y, Hao Y, Hong J. Advances in stent therapy for malignant biliary obstruction. Abdom Radiol (NY). 2021;46:351-361. [PMID: 32451676 DOI: 10.1007/s00261-020-02593-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
234 Rahnemai-Azar AA, Pawlik TM. Cholangiocarcinoma: shedding light on the most promising drugs in clinical development. Expert Opin Investig Drugs 2021;30:419-27. [PMID: 33645382 DOI: 10.1080/13543784.2021.1897103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
235 Lamarca A, Frizziero M, McNamara MG, Valle JW. Clinical and Translational Research Challenges in Biliary Tract Cancers. Curr Med Chem 2020;27:4756-77. [PMID: 31971102 DOI: 10.2174/0929867327666200123090153] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
236 Bednarsch J, Czigany Z, Heij LR, Liu D, den Dulk M, Wiltberger G, Bruners P, Ulmer TF, Neumann UP, Lang SA. Compelling Long-Term Results for Liver Resection in Early Cholangiocarcinoma. J Clin Med 2021;10:2959. [PMID: 34209368 DOI: 10.3390/jcm10132959] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
237 Chiang NJ, Chen LT, Shan YS, Yeh CN, Chen MH. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. Biomolecules 2021;11:97. [PMID: 33451059 DOI: 10.3390/biom11010097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
238 You J, Wang X. Circ_HIPK3 Knockdown Inhibits Cell Proliferation, Migration and Invasion of Cholangiocarcinoma Partly via Mediating the miR-148a-3p/ULK1 Pathway. Cancer Manag Res 2021;13:3827-39. [PMID: 34007215 DOI: 10.2147/CMAR.S293823] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
239 Kim Y, Lee K, Jeong S, Wen X, Cho N, Kang GH. DLEC1 methylation is associated with a better clinical outcome in patients with intrahepatic cholangiocarcinoma of the small duct subtype. Virchows Arch 2019;475:49-58. [DOI: 10.1007/s00428-018-02511-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
240 Balakrishnan M, Glover MT, Kanwal F. Hepatitis C and Risk of Nonhepatic Malignancies. Clinics in Liver Disease 2017;21:543-54. [DOI: 10.1016/j.cld.2017.03.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
241 Zaccari P, Cardinale V, Severi C, Pedica F, Carpino G, Gaudio E, Doglioni C, Petrone MC, Alvaro D, Arcidiacono PG, Capurso G. Common features between neoplastic and preneoplastic lesions of the biliary tract and the pancreas. World J Gastroenterol 2019; 25(31): 4343-4359 [PMID: 31496617 DOI: 10.3748/wjg.v25.i31.4343] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
242 Darbà J, Marsà A. Analysis of hospital incidence and direct medical costs of intrahepatic cholangiocarcinoma in Spain (2000-2018). Expert Rev Pharmacoecon Outcomes Res 2021;21:425-31. [PMID: 33161795 DOI: 10.1080/14737167.2021.1842201] [Reference Citation Analysis]
243 Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557-588. [PMID: 32606456 DOI: 10.1038/s41575-020-0310-z] [Cited by in Crossref: 160] [Cited by in F6Publishing: 167] [Article Influence: 80.0] [Reference Citation Analysis]
244 Kim M, Rhee H, Woo HY. A dichotomous imaging classification for cholangiocarcinomas based on new histologic concepts. European Journal of Radiology 2019;113:182-7. [DOI: 10.1016/j.ejrad.2019.02.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
245 Gradilone SA. Extracellular vesicles as therapeutic carriers of microRNAs for cholangiocarcinoma. Hepatology 2017;65:404-6. [PMID: 28012192 DOI: 10.1002/hep.28925] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
246 Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T, Melisi D, Macarulla T, Bridgewater J, Wasan H, Borad MJ, Abou-Alfa GK, Jiang P, Lihou CF, Zhen H, Asatiani E, Féliz L, Vogel A. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol 2020;16:2385-99. [PMID: 32677452 DOI: 10.2217/fon-2020-0429] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
247 Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, Ikeda M, Sasaki M, Okano N, Furuse J, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T. Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. Future Oncol 2022. [PMID: 35510484 DOI: 10.2217/fon-2022-0214] [Reference Citation Analysis]
248 Chen G, Cai Z, Dong X, Zhao J, Lin S, Hu X, Liu FE, Liu X, Zhang H. Genomic and Transcriptomic Landscape of Tumor Clonal Evolution in Cholangiocarcinoma. Front Genet 2020;11:195. [PMID: 32231683 DOI: 10.3389/fgene.2020.00195] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
249 Louis C, Papoutsoglou P, Coulouarn C. Molecular classification of cholangiocarcinoma. Curr Opin Gastroenterol. 2020;36: 57-62. [PMID: 31895230 DOI: 10.1097/mog.0000000000000611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
250 Yang G, Xiong Y, Sun J, Tang T, Li W, Wang G, Li J. Effects of different preoperative biliary drainage methods for resected malignant obstruction jaundice on the incidence rate of implantation metastasis: A meta-analysis. Oncol Lett 2020;20:2217-24. [PMID: 32782538 DOI: 10.3892/ol.2020.11767] [Reference Citation Analysis]
251 Mertens JC, Rizvi S, Gores GJ. Targeting cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis 2018;1864:1454-60. [PMID: 28844952 DOI: 10.1016/j.bbadis.2017.08.027] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
252 Peng YC, Lin CL, Hsu WY, Chow WK, Lee SW, Yeh HZ, Chen CC, Kao CH. Association Between Cholangiocarcinoma and Proton Pump Inhibitors Use: A Nested Case-Control Study. Front Pharmacol 2018;9:718. [PMID: 30018559 DOI: 10.3389/fphar.2018.00718] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
253 Turgeon MK, Maithel SK. Cholangiocarcinoma: a site-specific update on the current state of surgical management and multi-modality therapy. Chin Clin Oncol 2020;9:4. [PMID: 31500433 DOI: 10.21037/cco.2019.08.09] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
254 Kim D, Konyn P, Cholankeril G, Bonham CA, Ahmed A. Trends in the Mortality of Biliary Tract Cancers Based on Their Anatomical Site in the United States From 2009 to 2018. Am J Gastroenterol 2021;116:1053-62. [PMID: 33929380 DOI: 10.14309/ajg.0000000000001151] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
255 Ainthachot S, Sa-ngiamwibool P, Thanee M, Watcharadetwittaya S, Chamgramol Y, Pairojkul C, Deenonpoe R. Chromosomal aberrations, visualized using UroVysion® fluorescence in-situ hybridization assay, can predict poor prognosis in formalin-fixed paraffin-embedded tissues of cholangiocarcinoma patients. Human Pathology 2022. [DOI: 10.1016/j.humpath.2022.05.008] [Reference Citation Analysis]
256 Gupta R, Togashi J, Akamatsu N, Sakamoto Y, Kokudo N. Impact of incidental/misdiagnosed intrahepatic cholangiocarcinoma and combined hepatocellular cholangiocarcinoma on the outcomes of liver transplantation: an institutional case series and literature review. Surg Today 2017;47:908-17. [DOI: 10.1007/s00595-017-1472-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
257 Yoo C, Oh DY, Choi HJ, Kudo M, Ueno M, Kondo S, Chen LT, Osada M, Helwig C, Dussault I, Ikeda M. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer. J Immunother Cancer 2020;8:e000564. [PMID: 32461347 DOI: 10.1136/jitc-2020-000564] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 27.0] [Reference Citation Analysis]
258 Carotti S, Zingariello M, Francesconi M, D'Andrea L, Latasa MU, Colyn L, Fernandez-Barrena MG, Flammia RS, Falchi M, Righi D, Pedini G, Pantano F, Bagni C, Perrone G, Rana RA, Avila MA, Morini S, Zalfa F. Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge. Oncogene 2021;40:4033-49. [PMID: 34017076 DOI: 10.1038/s41388-021-01824-3] [Reference Citation Analysis]
259 Li F, Peiris MN, Donoghue DJ. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma. Cytokine Growth Factor Rev 2020;52:56-67. [PMID: 31899106 DOI: 10.1016/j.cytogfr.2019.12.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
260 Wu LM, Zhang LL, Chen XH, Zheng SS. Is irreversible electroporation safe and effective in the treatment of hepatobiliary and pancreatic cancers? Hepatobiliary Pancreat Dis Int. 2019;18:117-124. [PMID: 30655073 DOI: 10.1016/j.hbpd.2019.01.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
261 Song J, Cui D, Wang J, Qin J, Wang S, Wang Z, Zhai X, Ma H, Ma D, Liu Y, Jin B, Liu Z. Overexpression of HMGA1 confers radioresistance by transactivating RAD51 in cholangiocarcinoma. Cell Death Discov 2021;7:322. [PMID: 34716319 DOI: 10.1038/s41420-021-00721-8] [Reference Citation Analysis]
262 Procopio F, Branciforte B, Nappo G, Di Tommaso L, Lleo A, Torzilli G. Meta-analysis on prognostic value of KRAS mutation in resected mass-forming cholangiocarcinoma. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.03.005] [Reference Citation Analysis]
263 Hoyos S, Navas MC, Restrepo JC, Botero RC. Current controversies in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1461-1467. [PMID: 28756216 DOI: 10.1016/j.bbadis.2017.07.027] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
264 Bartolini I, Risaliti M, Fortuna L, Agostini C, Ringressi MN, Taddei A, Muiesan P. Current management of intrahepatic cholangiocarcinoma: from resection to palliative treatments. Radiol Oncol 2020;54:263-71. [PMID: 32726292 DOI: 10.2478/raon-2020-0045] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
265 Macias RIR, Kornek M, Rodrigues PM, Paiva NA, Castro RE, Urban S, Pereira SP, Cadamuro M, Rupp C, Loosen SH, Luedde T, Banales JM. Diagnostic and prognostic biomarkers in cholangiocarcinoma. Liver Int. 2019;39 Suppl 1:108-122. [PMID: 30843325 DOI: 10.1111/liv.14090] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 15.0] [Reference Citation Analysis]
266 Byrling J, Kristl T, Hu D, Pla I, Sanchez A, Sasor A, Andersson R, Marko-Varga G, Andersson B. Mass spectrometry-based analysis of formalin-fixed, paraffin-embedded distal cholangiocarcinoma identifies stromal thrombospondin-2 as a potential prognostic marker. J Transl Med 2020;18:343. [PMID: 32887625 DOI: 10.1186/s12967-020-02498-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
267 Raggi C, Gammella E, Correnti M, Buratti P, Forti E, Andersen JB, Alpini G, Glaser S, Alvaro D, Invernizzi P, Cairo G, Recalcati S. Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells. Sci Rep 2017;7:17667. [PMID: 29247214 DOI: 10.1038/s41598-017-17804-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
268 Casadio M, Biancaniello F, Overi D, Venere R, Carpino G, Gaudio E, Alvaro D, Cardinale V. Molecular Landscape and Therapeutic Strategies in Cholangiocarcinoma: An Integrated Translational Approach towards Precision Medicine. Int J Mol Sci 2021;22:5613. [PMID: 34070643 DOI: 10.3390/ijms22115613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
269 Baiocchi L, Zhou T, Liangpunsakul S, Lenci I, Santopaolo F, Meng F, Kennedy L, Glaser S, Francis H, Alpini G. Dual Role of Bile Acids on the Biliary Epithelium: Friend or Foe? Int J Mol Sci 2019;20:E1869. [PMID: 31014010 DOI: 10.3390/ijms20081869] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
270 Corrao S, Natoli G, Argano C. Nonalcoholic fatty liver disease is associated with intrahepatic cholangiocarcinoma and not with extrahepatic form: definitive evidence from meta-analysis and trial sequential analysis. Eur J Gastroenterol Hepatol 2021;33:62-8. [PMID: 32091438 DOI: 10.1097/MEG.0000000000001684] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
271 Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-wahab R, Gupta N, Mobley CM, Saharia A, Victor DW, Nguyen DT, Graviss EA, Kaseb AO, Mcfadden RS, Aloia TA, Conrad C, Li XC, Monsour HP, Gaber AO, Vauthey J, Ghobrial RM. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. The Lancet Gastroenterology & Hepatology 2018;3:337-48. [DOI: 10.1016/s2468-1253(18)30045-1] [Cited by in Crossref: 74] [Cited by in F6Publishing: 33] [Article Influence: 18.5] [Reference Citation Analysis]
272 Carnevale G, Carpino G, Cardinale V, Pisciotta A, Riccio M, Bertoni L, Gibellini L, De Biasi S, Nevi L, Costantini D, Overi D, Cossarizza A, de Pol A, Gaudio E, Alvaro D. Activation of Fas/FasL pathway and the role of c-FLIP in primary culture of human cholangiocarcinoma cells. Sci Rep. 2017;7:14419. [PMID: 29089545 DOI: 10.1038/s41598-017-14838-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
273 Macias RIR, Muñoz-Bellvís L, Sánchez-Martín A, Arretxe E, Martínez-Arranz I, Lapitz A, Gutiérrez ML, La Casta A, Alonso C, González LM, Avila MA, Martinez-Chantar ML, Castro RE, Bujanda L, Banales JM, Marin JJG. A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2020;12:E1433. [PMID: 32486461 DOI: 10.3390/cancers12061433] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
274 Kendall T, Verheij J, Gaudio E, Evert M, Guido M, Goeppert B, Carpino G. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019;39 Suppl 1:7-18. [PMID: 30882996 DOI: 10.1111/liv.14093] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 33.5] [Reference Citation Analysis]
275 Rizzo A, Ricci AD, Brandi G. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. Expert Opinion on Investigational Drugs 2021;30:317-24. [DOI: 10.1080/13543784.2021.1837774] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
276 Loeffler MA, Hu J, Kirchner M, Wei X, Xiao Y, Albrecht T, De La Torre C, Sticht C, Banales JM, Vogel MN, Pathil-Warth A, Mehrabi A, Hoffmann K, Rupp C, Köhler B, Springfeld C, Schirmacher P, Ji J, Roessler S, Goeppert B. miRNA profiling of biliary intraepithelial neoplasia reveals stepwise tumorigenesis in distal cholangiocarcinoma via the miR-451a/ATF2 axis. J Pathol 2020;252:239-51. [PMID: 32710569 DOI: 10.1002/path.5514] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
277 Rizzo A, Ricci AD, Brandi G. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? Cancer Treat Res Commun 2021;27:100356. [PMID: 33799004 DOI: 10.1016/j.ctarc.2021.100356] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
278 Carpino G, Cardinale V, Folseraas T, Overi D, Grzyb K, Costantini D, Berloco PB, Di Matteo S, Karlsen TH, Alvaro D, Gaudio E. Neoplastic Transformation of the Peribiliary Stem Cell Niche in Cholangiocarcinoma Arisen in Primary Sclerosing Cholangitis. Hepatology 2019;69:622-38. [DOI: 10.1002/hep.30210] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
279 Roos E, Franken LC, Soer EC, van Hooft JE, Takkenberg RB, Klümpen HJ, Wilmink JW, van de Vijver MJ, van Gulik TM, Verheij J. Lost in translation: confusion on resection and dissection planes hampers the interpretation of pathology reports for perihilar cholangiocarcinoma. Virchows Arch 2019;475:435-43. [PMID: 31446465 DOI: 10.1007/s00428-019-02621-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
280 Ji GW, Wang K, Xia YX, Wang JS, Wang XH, Li XC. Integrating Machine Learning and Tumor Immune Signature to Predict Oncologic Outcomes in Resected Biliary Tract Cancer. Ann Surg Oncol 2021;28:4018-29. [PMID: 33230745 DOI: 10.1245/s10434-020-09374-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
281 Tusskorn O, Khunluck T, Prawan A, Senggunprai L, Kukongviriyapan U, Kukongviriyapan V. Suppression of glutathione S-transferases potentiates the cytotoxic effect of phenethyl isothiocyanate in cholangiocarcinoma cells. Naunyn Schmiedebergs Arch Pharmacol 2018;391:657-67. [PMID: 29666895 DOI: 10.1007/s00210-018-1492-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
282 Goeppert B, Renner M, Singer S, Albrecht T, Zhang Q, Mehrabi A, Pathil A, Springfeld C, Köhler B, Rupp C, Weiss KH, Kühl AA, Arsenic R, Pape UF, Vogel A, Schirmacher P, Roessler S, Utku N. Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma. Sci Rep 2019;9:4338. [PMID: 30867471 DOI: 10.1038/s41598-019-40487-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
283 Prat F. Suspected malignant biliary strictures: from inside out or outside in? Endosc Int Open 2018;6:E778-9. [PMID: 29881769 DOI: 10.1055/s-0044-101353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
284 Augustin J, Gabignon C, Scriva A, Menu L, Calmel C, Scatton O, Paye F, Fléjou JF, Praz F, Cervera P, Wendum D. Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas. Virchows Arch 2020;477:33-45. [PMID: 32447492 DOI: 10.1007/s00428-020-02822-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
285 Pastore M, Lori G, Gentilini A, Taddei ML, Di Maira G, Campani C, Recalcati S, Invernizzi P, Marra F, Raggi C. Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives. Cells 2020;9:E596. [PMID: 32138158 DOI: 10.3390/cells9030596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
286 Olaizola P, Perugorria MJ, Banales JM. Toward personalized medicine for intrahepatic cholangiocarcinoma: Pharmacogenomic stratification of patients. Hepatology 2018;68:811-4. [PMID: 29394502 DOI: 10.1002/hep.29830] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
287 Wang X, Yu GY, Chen M, Wei R, Chen J, Wang Z. Pattern of distant metastases in primary extrahepatic bile-duct cancer: A SEER-based study. Cancer Med 2018;7:5006-14. [PMID: 30277653 DOI: 10.1002/cam4.1772] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
288 Rupp C, Bode KA, Leopold Y, Sauer P, Gotthardt DN. Pathological features of primary sclerosing cholangitis identified by bile proteomic analysis. Biochim Biophys Acta Mol Basis Dis 2018;1864:1380-9. [PMID: 28943450 DOI: 10.1016/j.bbadis.2017.09.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
289 Burkhart RA, Pawlik TM. Staging and Prognostic Models for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control 2017;24:1073274817729235. [PMID: 28975828 DOI: 10.1177/1073274817729235] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
290 Kaffe E, Magkrioti C, Aidinis V. Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer. Cancers (Basel) 2019;11:E1626. [PMID: 31652837 DOI: 10.3390/cancers11111626] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
291 Rizzo A, Ricci AD, Brandi G. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer. Cancers (Basel) 2021;13:558. [PMID: 33535621 DOI: 10.3390/cancers13030558] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 25.0] [Reference Citation Analysis]
292 Mima K, Kosumi K, Baba Y, Hamada T, Baba H, Ogino S. The microbiome, genetics, and gastrointestinal neoplasms: the evolving field of molecular pathological epidemiology to analyze the tumor-immune-microbiome interaction. Hum Genet 2021;140:725-46. [PMID: 33180176 DOI: 10.1007/s00439-020-02235-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
293 Chahal D, Shamatutu C, Salh B, Davies J. The impact of primary sclerosing cholangitis or inflammatory bowel disease on cholangiocarcinoma phenotype, therapy, and survival. JGH Open 2020;4:1128-34. [PMID: 33319047 DOI: 10.1002/jgh3.12405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
294 Wu Q, Fan H, Lang R, Li X, Zhang X, Lv S, He Q. Overexpression of 14-3-3σ Modulates Cholangiocarcinoma Cell Survival by PI3K/Akt Signaling. Biomed Res Int 2020;2020:3740418. [PMID: 32685476 DOI: 10.1155/2020/3740418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
295 Rizzo A, Ricci AD, Brandi G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol 2021;15:527-36. [PMID: 33215952 DOI: 10.1080/17474124.2021.1853527] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
296 Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399:61-116. [PMID: 34863359 DOI: 10.1016/S0140-6736(21)01701-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
297 Akateh C, Ejaz AM, Pawlik TM, Cloyd JM. Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. World J Hepatol 2020; 12(10): 693-708 [PMID: 33200010 DOI: 10.4254/wjh.v12.i10.693] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
298 Aghili M, Saberi H, Zadeh MM, Jafari F, Mehrabinejad MM, Dashti H, Saberi P, Yazdi NA. Multimodality treatment in unresectable cholangiocarcinoma. J Contemp Brachytherapy 2020;12:131-8. [PMID: 32395137 DOI: 10.5114/jcb.2020.94582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
299 Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. J Hepatol 2020;73:170-85. [PMID: 32171892 DOI: 10.1016/j.jhep.2020.03.007] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 37.5] [Reference Citation Analysis]
300 Li Y, Zhou Y, Hong Y, He M, Wei S, Yang C, Zheng D, Liu F. The Efficacy of Different Chemotherapy Regimens for Advanced Biliary Tract Cancer: A Systematic Review and Network Meta-Analysis. Front Oncol 2019;9:441. [PMID: 31192137 DOI: 10.3389/fonc.2019.00441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
301 Hou L, Jiang J, Liu B, Han W, Wu Y, Zou X, Xue F, Chen Y, Zhang B, Pang H, Wang Y, Wang Z, Hu Y, Li J. Is exposure to tobacco associated with extrahepatic cholangiocarcinoma epidemics? A retrospective proportional mortality study in China. BMC Cancer 2019;19:348. [PMID: 30975121 DOI: 10.1186/s12885-019-5484-9] [Reference Citation Analysis]
302 Colyn L, Bárcena-Varela M, Álvarez-Sola G, Latasa MU, Uriarte I, Santamaría E, Herranz JM, Santos-Laso A, Arechederra M, Ruiz de Gauna M, Aspichueta P, Canale M, Casadei-Gardini A, Francesconi M, Carotti S, Morini S, Nelson LJ, Iraburu MJ, Chen C, Sangro B, Marin JJG, Martinez-Chantar ML, Banales JM, Arnes-Benito R, Huch M, Patino JM, Dar AA, Nosrati M, Oyarzábal J, Prósper F, Urman J, Cubero FJ, Trautwein C, Berasain C, Fernandez-Barrena MG, Avila MA. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma. Hepatology 2021;73:2380-96. [PMID: 33222246 DOI: 10.1002/hep.31642] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
303 Alnaggar M, Xu Y, Li J, He J, Chen J, Li M, Wu Q, Lin L, Liang Y, Wang X, Li J, Hu Y, Chen Y, Xu K, Wu Y, Yin Z. Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma. J Immunother Cancer 2019;7:36. [PMID: 30736852 DOI: 10.1186/s40425-019-0501-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 10.7] [Reference Citation Analysis]
304 Rizzo A, Ricci AD, Cusmai A, Acquafredda S, De Palma G, Brandi G, Palmiotti G. Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future. Current Oncology 2022;29:551-64. [DOI: 10.3390/curroncol29020050] [Reference Citation Analysis]
305 Pitcairn CFM, Kawka M. Contrast-enhanced ultrasonography for intrahepatic cholangiocarcinoma: A cost-effective alternative for low-resource settings. Hepatobiliary Pancreat Dis Int 2021;20:304-5. [PMID: 33349606 DOI: 10.1016/j.hbpd.2020.12.012] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
306 Cadamuro M, Stecca T, Brivio S, Mariotti V, Fiorotto R, Spirli C, Strazzabosco M, Fabris L. The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis 2018;1864:1435-43. [PMID: 28757170 DOI: 10.1016/j.bbadis.2017.07.028] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
307 Wang Y, Chen T, Li K, Mu W, Liu Z, Shi A, Liu J, Zhao W, Lian S, Huang S, Pan C, Zhang Z. Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer. Front Oncol 2021;11:777617. [PMID: 34778094 DOI: 10.3389/fonc.2021.777617] [Reference Citation Analysis]
308 Li J, Moustafa M, Linecker M, Lurje G, Capobianco I, Baumgart J, Ratti F, Rauchfuss F, Balci D, Fernandes E, Montalti R, Robles-Campos R, Bjornsson B, Topp SA, Fronek J, Liu C, Wahba R, Bruns C, Brunner SM, Schlitt HJ, Heumann A, Stüben BO, Izbicki JR, Bednarsch J, Gringeri E, Fasolo E, Rolinger J, Kristek J, Hernandez-Alejandro R, Schnitzbauer A, Nuessler N, Schön MR, Voskanyan S, Petrou AS, Hahn O, Soejima Y, Vicente E, Castro-Benitez C, Adam R, Tomassini F, Troisi RI, Kantas A, Oldhafer KJ, Ardiles V, de Santibanes E, Malago M, Clavien PA, Vivarelli M, Settmacher U, Aldrighetti L, Neumann U, Petrowsky H, Cillo U, Lang H, Nadalin S. ALPPS for Locally Advanced Intrahepatic Cholangiocarcinoma: Did Aggressive Surgery Lead to the Oncological Benefit? An International Multi-center Study. Ann Surg Oncol 2020;27:1372-84. [PMID: 32002719 DOI: 10.1245/s10434-019-08192-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 12.5] [Reference Citation Analysis]
309 Mancinelli R, Carpino G, Petrungaro S, Mammola CL, Tomaipitinca L, Filippini A, Facchiano A, Ziparo E, Giampietri C. Multifaceted Roles of GSK-3 in Cancer and Autophagy-Related Diseases. Oxid Med Cell Longev 2017;2017:4629495. [PMID: 29379583 DOI: 10.1155/2017/4629495] [Cited by in Crossref: 71] [Cited by in F6Publishing: 79] [Article Influence: 14.2] [Reference Citation Analysis]
310 Kim YY, Yeom SK, Shin H, Choi SH, Rhee H, Park JH, Cho ES, Park S, Lee SS, Park MS. Clinical Staging of Mass-Forming Intrahepatic Cholangiocarcinoma: Computed Tomography Versus Magnetic Resonance Imaging. Hepatol Commun 2021;5:2009-18. [PMID: 34559470 DOI: 10.1002/hep4.1774] [Reference Citation Analysis]
311 Roy S, Glaser S, Chakraborty S. Inflammation and Progression of Cholangiocarcinoma: Role of Angiogenic and Lymphangiogenic Mechanisms. Front Med (Lausanne). 2019;6:293. [PMID: 31921870 DOI: 10.3389/fmed.2019.00293] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
312 Goeppert B, Roessler S, Renner M, Singer S, Mehrabi A, Vogel MN, Pathil A, Czink E, Köhler B, Springfeld C, Pfeiffenberger J, Rupp C, Weiss KH, Schirmacher P, von Knebel Doeberitz M, Kloor M. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma. Br J Cancer 2019;120:109-14. [PMID: 30377340 DOI: 10.1038/s41416-018-0199-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
313 Chatchawal P, Wongwattanakul M, Tippayawat P, Kochan K, Jearanaikoon N, Wood BR, Jearanaikoon P. Detection of Human Cholangiocarcinoma Markers in Serum Using Infrared Spectroscopy. Cancers (Basel) 2021;13:5109. [PMID: 34680259 DOI: 10.3390/cancers13205109] [Reference Citation Analysis]
314 He C, Zhao C, Zhang Y, Chen C, Lin X. An Inflammation-Index Signature Predicts Prognosis of Patients with Intrahepatic Cholangiocarcinoma After Curative Resection. J Inflamm Res 2021;14:1859-72. [PMID: 34012285 DOI: 10.2147/JIR.S311084] [Reference Citation Analysis]
315 Perez-Montoyo H. Therapeutic Potential of Autophagy Modulation in Cholangiocarcinoma. Cells 2020;9:E614. [PMID: 32143356 DOI: 10.3390/cells9030614] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
316 Thongchot S, Vidoni C, Ferraresi A, Loilome W, Yongvanit P, Namwat N, Isidoro C. Dihydroartemisinin induces apoptosis and autophagy-dependent cell death in cholangiocarcinoma through a DAPK1-BECLIN1 pathway. Mol Carcinog. 2018;57:1735-1750. [PMID: 30136419 DOI: 10.1002/mc.22893] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
317 Ruzittu S, Willnow D, Spagnoli FM. Direct Lineage Reprogramming: Harnessing Cell Plasticity between Liver and Pancreas. Cold Spring Harb Perspect Biol 2020;12:a035626. [PMID: 31767653 DOI: 10.1101/cshperspect.a035626] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
318 Shi G, Zhang H, Yu Q, Hu C, Ji Y. GATA1 gene silencing inhibits invasion, proliferation and migration of cholangiocarcinoma stem cells via disrupting the PI3K/AKT pathway. Onco Targets Ther 2019;12:5335-54. [PMID: 31456644 DOI: 10.2147/OTT.S198750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
319 Gringeri E, Gambato M, Sapisochin G, Ivanics T, Lynch EN, Mescoli C, Burra P, Cillo U, Russo FP. Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology. J Clin Med 2020;9:E1353. [PMID: 32380750 DOI: 10.3390/jcm9051353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
320 Shiraki T, Kuroda H, Takada A, Nakazato Y, Kubota K, Imai Y. Intraoperative frozen section diagnosis of bile duct margin for extrahepatic cholangiocarcinoma. World J Gastroenterol 2018; 24(12): 1332-1342 [PMID: 29599608 DOI: 10.3748/wjg.v24.i12.1332] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
321 Raggi C, Fiaccadori K, Pastore M, Correnti M, Piombanti B, Forti E, Navari N, Abbadessa G, Hall T, Destro A, Di Tommaso L, Roncalli M, Meng F, Glaser S, Rovida E, Peraldo-Neia C, Olaizola P, Banales JM, Gerussi A, Elvevi A, Droz Dit Busset M, Bhoori S, Mazzaferro V, Alpini G, Marra F, Invernizzi P. Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma. Am J Pathol 2019;189:2090-101. [PMID: 31351075 DOI: 10.1016/j.ajpath.2019.06.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
322 Rizvi S, Gores GJ. Emerging molecular therapeutic targets for cholangiocarcinoma. J Hepatol 2017;67:632-44. [PMID: 28389139 DOI: 10.1016/j.jhep.2017.03.026] [Cited by in Crossref: 79] [Cited by in F6Publishing: 78] [Article Influence: 15.8] [Reference Citation Analysis]
323 Wu Q, Fan H, Lang R, Li X, Zhang X, Lv S, He Q. Overexpression of 14-3-3δ Predicts Poor Prognosis in Extrahepatic Cholangiocarcinoma Patients. Biomed Res Int 2020;2020:8435420. [PMID: 32685532 DOI: 10.1155/2020/8435420] [Reference Citation Analysis]
324 Sawada R, Ku Y, Akita M, Otani K, Fujikura K, Itoh T, Ajiki T, Fukumoto T, Kakeji Y, Zen Y. Interleukin-33 overexpression reflects less aggressive tumour features in large-duct type cholangiocarcinomas. Histopathology 2018;73:259-72. [DOI: 10.1111/his.13633] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
325 Bitzer M, Spahn S, Babaei S, Horger M, Singer S, Schulze-Osthoff K, Missios P, Gatidis S, Nann D, Mattern S, Scheble V, Nikolaou K, Armeanu-Ebinger S, Schulze M, Schroeder C, Biskup S, Beha J, Claassen M, Ruhm K, Poso A, Malek NP. Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma. NPJ Precis Oncol 2021;5:80. [PMID: 34480077 DOI: 10.1038/s41698-021-00220-0] [Reference Citation Analysis]
326 Cheng X, Zhao F, Chen D, Yang P, Zhong W, Xu X, Wang W. Successful treatment of colorectal liver metastasis harboring intrahepatic cholangiocarcinoma: A case report. Medicine (Baltimore) 2018;97:e13751. [PMID: 30572520 DOI: 10.1097/MD.0000000000013751] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
327 Rizzo A, Brandi G. Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions. Cancer Treat Res Commun 2021;27:100334. [PMID: 33592563 DOI: 10.1016/j.ctarc.2021.100334] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
328 Hemming AW. Biliary Tract and Primary Liver Tumors. Surgical Oncology Clinics of North America 2019;28:519-38. [DOI: 10.1016/j.soc.2019.06.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
329 Boilève A, Verlingue L, Hollebecque A, Boige V, Ducreux M, Malka D. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers. Expert Opin Investig Drugs 2021;30:401-9. [PMID: 33641556 DOI: 10.1080/13543784.2021.1896703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
330 Yangngam S, Thongchot S, Pongpaibul A, Vaeteewoottacharn K, Pinlaor S, Thuwajit P, Okada S, Hermoso MA, Thuwajit C. High level of interleukin-33 in cancer cells and cancer-associated fibroblasts correlates with good prognosis and suppressed migration in cholangiocarcinoma. J Cancer 2020;11:6571-81. [PMID: 33046978 DOI: 10.7150/jca.48327] [Reference Citation Analysis]
331 Yosudjai J, Wongkham S, Jirawatnotai S, Kaewkong W. Aberrant mRNA splicing generates oncogenic RNA isoforms and contributes to the development and progression of cholangiocarcinoma. Biomed Rep 2019;10:147-55. [PMID: 30906543 DOI: 10.3892/br.2019.1188] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
332 Schwab ME, Song H, Mattis A, Phelps A, Vu LT, Huang FW, Nijagal A. De novo somatic mutations and KRAS amplification are associated with cholangiocarcinoma in a patient with a history of choledochal cyst. J Pediatr Surg 2020;55:2657-61. [PMID: 32295706 DOI: 10.1016/j.jpedsurg.2020.03.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
333 Jala I, Almanfaluthi ML, Laha T, Kanthawong S, Tangkawattana S, Saichua P, Suttiprapa S, Sripa B. Helicobacter pylori GroEL Seropositivity Is Associated with an Increased Risk of Opisthorchis viverrini-Associated Hepatobiliary Abnormalities and Cholangiocarcinoma. Korean J Parasitol 2021;59:363-8. [PMID: 34470087 DOI: 10.3347/kjp.2021.59.4.363] [Reference Citation Analysis]
334 Gao Y, Zhang H, Zhou N, Xu P, Wang J, Gao Y, Jin X, Liang X, Lv J, Zhang Y, Tang K, Ma J, Zhang H, Xie J, Yao F, Tong W, Liu Y, Wang X, Huang B. Methotrexate-loaded tumour-cell-derived microvesicles can relieve biliary obstruction in patients with extrahepatic cholangiocarcinoma. Nat Biomed Eng 2020;4:743-53. [PMID: 32632227 DOI: 10.1038/s41551-020-0583-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
335 Cadamuro M, Brivio S, Stecca T, Kaffe E, Mariotti V, Milani C, Fiorotto R, Spirli C, Strazzabosco M, Fabris L. Animal models of cholangiocarcinoma: What they teach us about the human disease. Clin Res Hepatol Gastroenterol 2018;42:403-15. [PMID: 29753731 DOI: 10.1016/j.clinre.2018.04.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
336 Liang J, Liu T, Liao J, Zhang L, Zhou M, Xu W, He Y, Cai G, Jin G, Song J, Li G, Liang H, Ding Z, Zhang B. Development and validation of a CpG island methylator phenotype-related prognostic signature for cholangiocarcinoma. J Cell Physiol 2021;236:3143-56. [PMID: 32996133 DOI: 10.1002/jcp.30082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
337 Cruz-Ramón V, Chinchilla-López P, Ramírez-Pérez O, Qi X, Méndez-Sánchez N. The Changing Face of the Diagnosis of Chronic and Malignant Liver Diseases: Potential New Biomarkers. Ann Hepatol 2018;17:14-7. [PMID: 29311406 DOI: 10.5604/01.3001.0010.7531] [Reference Citation Analysis]
338 Tummanatsakun D, Proungvitaya T, Roytrakul S, Proungvitaya S. Bioinformatic Prediction of Signaling Pathways for Apurinic/Apyrimidinic Endodeoxyribonuclease 1 (APEX1) and Its Role in Cholangiocarcinoma Cells. Molecules 2021;26:2587. [PMID: 33946672 DOI: 10.3390/molecules26092587] [Reference Citation Analysis]
339 Kakisaka K, Endo K, Sugimoto R, Ishida K, Sugai T, Takikawa Y. Budd-Chiari Syndrome and Esophageal Achalasia: Unrecognized Intrahepatic Cholangiocarcinoma Invading Multiple Organs. Intern Med 2018;57:2197-201. [PMID: 29526953 DOI: 10.2169/internalmedicine.0448-17] [Reference Citation Analysis]
340 Høgdall D, Larsen OF, Linnemann D, Svenstrup Poulsen T, Høgdall EV. Exome sequencing of 22 genes using tissue from patients with biliary tract cancer. APMIS 2020;128:3-9. [PMID: 31628675 DOI: 10.1111/apm.13003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
341 Padthaisong S, Thanee M, Namwat N, Phetcharaburanin J, Klanrit P, Khuntikeo N, Titapun A, Sungkhamanon S, Saya H, Loilome W. Overexpression of a panel of cancer stem cell markers enhances the predictive capability of the progression and recurrence in the early stage cholangiocarcinoma. J Transl Med 2020;18:64. [PMID: 32039729 DOI: 10.1186/s12967-020-02243-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
342 Hu F, Liu C, Xie F, Lin X, Yang J, Wang C, Huang Q. MSI2 knockdown represses extrahepatic cholangiocarcinoma growth and invasion by inhibiting epithelial-mesenchymal transition. Onco Targets Ther 2018;11:4035-46. [PMID: 30034243 DOI: 10.2147/OTT.S170739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
343 Yin L, Zhao S, Zhu H, Ji G, Zhang X. Primary tumor resection improves survival in patients with multifocal intrahepatic cholangiocarcinoma based on a population study. Sci Rep 2021;11:12166. [PMID: 34108604 DOI: 10.1038/s41598-021-91823-x] [Reference Citation Analysis]
344 Vaquero J, Guedj N, Clapéron A, Nguyen Ho-bouldoires TH, Paradis V, Fouassier L. Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks. Journal of Hepatology 2017;66:424-41. [DOI: 10.1016/j.jhep.2016.09.010] [Cited by in Crossref: 55] [Cited by in F6Publishing: 63] [Article Influence: 11.0] [Reference Citation Analysis]
345 Rathi S, Dhiman RK. Hepatobiliary Quiz Answers - 18 (2016). J Clin Exp Hepatol 2016;6:159-63. [PMID: 27493465 DOI: 10.1016/j.jceh.2016.06.174] [Reference Citation Analysis]
346 Rizzo A, Dadduzio V, Lombardi L, Ricci AD, Gadaleta-Caldarola G. Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges. Curr Oncol 2021;28:3393-402. [PMID: 34590592 DOI: 10.3390/curroncol28050293] [Reference Citation Analysis]
347 Erice O, Labiano I, Arbelaiz A, Santos-laso A, Munoz-garrido P, Jimenez-agüero R, Olaizola P, Caro-maldonado A, Martín-martín N, Carracedo A, Lozano E, Marin J, O'rourke C, Andersen J, Llop J, Gómez-vallejo V, Padro D, Martin A, Marzioni M, Adorini L, Trauner M, Bujanda L, Perugorria M, Banales J. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018;1864:1335-44. [DOI: 10.1016/j.bbadis.2017.08.016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
348 Wei F, Wang G, Ding J, Dou C, Yu T, Zhang C. Is It Time to Consider Laparoscopic Hepatectomy for Intrahepatic Cholangiocarcinoma? A Meta-Analysis. J Gastrointest Surg 2020;24:2244-50. [PMID: 31621026 DOI: 10.1007/s11605-019-04404-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
349 Jödicke L, Zender L, Malek NP. [Personalized treatment of cholangiocellular carcinoma (CCA)]. Internist (Berl) 2020;61:170-4. [PMID: 31938815 DOI: 10.1007/s00108-019-00723-w] [Reference Citation Analysis]
350 Rizzo A, Brandi G. Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer. Expert Review of Gastroenterology & Hepatology 2021;15:547-54. [DOI: 10.1080/17474124.2021.1890031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
351 Lomphithak T, Akara-Amornthum P, Murakami K, Hashimoto M, Usubuchi H, Iwabuchi E, Unno M, Cai Z, Sasano H, Jitkaew S. Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma. Sci Rep 2021;11:11743. [PMID: 34083572 DOI: 10.1038/s41598-021-89977-9] [Reference Citation Analysis]
352 Rodrigues PM, Vogel A, Arrese M, Balderramo DC, Valle JW, Banales JM. Next-Generation Biomarkers for Cholangiocarcinoma. Cancers (Basel) 2021;13:3222. [PMID: 34203269 DOI: 10.3390/cancers13133222] [Reference Citation Analysis]
353 Alsaleh M, Leftley Z, Barbera TA, Sithithaworn P, Khuntikeo N, Loilome W, Yongvanit P, Cox IJ, Chamodol N, Syms RR, Andrews RH, Taylor-Robinson SD. Cholangiocarcinoma: a guide for the nonspecialist. Int J Gen Med 2019;12:13-23. [PMID: 30588065 DOI: 10.2147/IJGM.S186854] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
354 Lamarca A, Edeline J, McNamara MG, Hubner RA, Nagino M, Bridgewater J, Primrose J, Valle JW. Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treat Rev. 2020;84:101936. [PMID: 31986437 DOI: 10.1016/j.ctrv.2019.101936] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
355 Dumonceau JM, Delhaye M, Charette N, Farina A. Challenging biliary strictures: pathophysiological features, differential diagnosis, diagnostic algorithms, and new clinically relevant biomarkers - part 1.Therap Adv Gastroenterol. 2020;13:1756284820927292. [PMID: 32595761 DOI: 10.1177/1756284820927292] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
356 Ness JR, Molvar C. Radioembolization of Intrahepatic Cholangiocarcinoma: Patient Selection, Outcomes, and Competing Therapies. Semin Intervent Radiol 2021;38:438-44. [PMID: 34629711 DOI: 10.1055/s-0041-1735526] [Reference Citation Analysis]
357 Jin W. ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications. J Clin Med 2020;9:E2255. [PMID: 32708604 DOI: 10.3390/jcm9072255] [Reference Citation Analysis]
358 Uhl B, Dietrich D, Branchi V, Semaan A, Schaefer P, Gevensleben H, Rostamzadeh B, Lingohr P, Schäfer N, Kalff JC, Kristiansen G, Matthaei H. DNA Methylation of PITX2 and PANCR Is Prognostic for Overall Survival in Patients with Resected Adenocarcinomas of the Biliary Tract. PLoS One 2016;11:e0165769. [PMID: 27798672 DOI: 10.1371/journal.pone.0165769] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
359 Rizzo A, Ricci AD, Frega G, Di Federico A, Brandi G. FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue. Expert Rev Gastroenterol Hepatol 2021;15:567-74. [PMID: 33787429 DOI: 10.1080/17474124.2021.1911646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
360 Lozano E, Macias RI, Monte MJ, Asensio M, Carmen S, Sanchez‐vicente L, Alonso‐peña M, Al‐abdulla R, Munoz‐garrido P, Satriano L, O'rourke CJ, Banales JM, Avila MA, Martinez‐chantar ML, Andersen JB, Briz O, Marin JJ. Causes of hOCT1‐Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor‐Selective Gene Therapy. Hepatology 2019;70:1246-61. [DOI: 10.1002/hep.30656] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
361 Le VH, O'Connor VV, Li D, Melstrom LG, Fong Y, DiFronzo AL. Outcomes of neoadjuvant therapy for cholangiocarcinoma: A review of existing evidence assessing treatment response and R0 resection rate. J Surg Oncol 2021;123:164-71. [PMID: 32974932 DOI: 10.1002/jso.26230] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
362 Lin J, Yan L, Wang X, Wu Z, Ke K, Lin X, Huang N, Yang W, Xia C. Administration of Iodine-125 Seeds Promotes Apoptosis in Cholangiocarcinoma through the PI3K/Akt Pathway. Advances in Polymer Technology 2022;2022:1-6. [DOI: 10.1155/2022/6934934] [Reference Citation Analysis]
363 Roy S, Kumaravel S, Banerjee P, White TK, O'Brien A, Seelig C, Chauhan R, Ekser B, Bayless KJ, Alpini G, Glaser SS, Chakraborty S. Tumor Lymphatic Interactions Induce CXCR2-CXCL5 Axis and Alter Cellular Metabolism and Lymphangiogenic Pathways to Promote Cholangiocarcinoma. Cells 2021;10:3093. [PMID: 34831316 DOI: 10.3390/cells10113093] [Reference Citation Analysis]
364 Wang M, Chen Z, Guo P, Wang Y, Chen G. Therapy for advanced cholangiocarcinoma: Current knowledge and future potential. J Cell Mol Med 2021;25:618-28. [PMID: 33277810 DOI: 10.1111/jcmm.16151] [Reference Citation Analysis]
365 Carotenuto M, Sacco A, Forgione L, Normanno N. Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy. Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2022.00079] [Reference Citation Analysis]
366 Liu T, Zhu G, Yan W, Lv Y, Wang X, Jin G, Cui M, Lin Z, Ren X. Cordycepin Inhibits Cancer Cell Proliferation and Angiogenesis through a DEK Interaction via ERK Signaling in Cholangiocarcinoma. J Pharmacol Exp Ther 2020;373:279-89. [DOI: 10.1124/jpet.119.263202] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
367 O'Brien A, Zhou T, Tan C, Alpini G, Glaser S. Role of Non-Coding RNAs in the Progression of Liver Cancer: Evidence from Experimental Models. Cancers (Basel) 2019;11:E1652. [PMID: 31731549 DOI: 10.3390/cancers11111652] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
368 Kamal H, Sadr-Azodi O, Engstrand L, Brusselaers N. Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study. Hepatology 2021. [PMID: 34018229 DOI: 10.1002/hep.31914] [Reference Citation Analysis]
369 Zeng FL, Chen JF. Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma. Technol Cancer Res Treat 2021;20:15330338211039952. [PMID: 34528830 DOI: 10.1177/15330338211039952] [Reference Citation Analysis]
370 Karam D, Agrawal B, Mouli C. Digital lesion leading to diagnosis of cholangiocarcinoma. BMJ Case Rep 2017;2017:bcr-2017-221075. [PMID: 28978591 DOI: 10.1136/bcr-2017-221075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
371 Viganò L, Lleo A, Muglia R, Gennaro N, Samà L, Colapietro F, Roncalli M, Aghemo A, Chiti A, Di Tommaso L, Solbiati L, Colombo M, Torzilli G. Intrahepatic cholangiocellular carcinoma with radiological enhancement patterns mimicking hepatocellular carcinoma. Updates Surg 2020;72:413-21. [PMID: 32323164 DOI: 10.1007/s13304-020-00750-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
372 Neuzillet C. Infigratinib in pretreated cholangiocarcinoma with FGFR2 fusions or rearrangements. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00220-X. [PMID: 34358483 DOI: 10.1016/S2468-1253(21)00220-X] [Reference Citation Analysis]
373 Pei SN, Liao CK, Chen YS, Tseng CH, Hung CM, Chiu CC, Hsieh MC, Tsai YF, Liao HY, Liu WC, Rau KM. A Novel Combination of Bevacizumab with Chemotherapy Improves Therapeutic Effects for Advanced Biliary Tract Cancer: A Retrospective, Observational Study. Cancers (Basel) 2021;13:3831. [PMID: 34359732 DOI: 10.3390/cancers13153831] [Reference Citation Analysis]
374 Moazzami B, Majidzadeh-A K, Dooghaie-Moghadam A, Eslami P, Razavi-Khorasani N, Iravani S, Khoshdel A, Shahi F, Dashti H, Mehrvar A, Nassiri Toosi M. Cholangiocarcinoma: State of the Art. J Gastrointest Cancer 2020;51:774-81. [PMID: 32157571 DOI: 10.1007/s12029-020-00390-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
375 Wang L, Lin N, Xin F, Ke Q, Zeng Y, Liu J. A systematic review of the comparison of the incidence of seeding metastasis between endoscopic biliary drainage and percutaneous transhepatic biliary drainage for resectable malignant biliary obstruction. World J Surg Oncol 2019;17:116. [PMID: 31277666 DOI: 10.1186/s12957-019-1656-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
376 Fernández-Barrena MG, Perugorria MJ, Banales JM. Novel lncRNA T-UCR as a potential downstream driver of the Wnt/β-catenin pathway in hepatobiliary carcinogenesis. Gut 2017;66:1177-8. [PMID: 27986786 DOI: 10.1136/gutjnl-2016-312899] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
377 Tominaga H, Matsuzaki J, Oikawa C, Toyoshima K, Manabe H, Ozawa E, Shimamura A, Yokoyama R, Serizawa Y, Ochiya T, Saito Y. Challenges for Better Diagnosis and Management of Pancreatic and Biliary Tract Cancers Focusing on Blood Biomarkers: A Systematic Review. Cancers (Basel) 2021;13:4220. [PMID: 34439378 DOI: 10.3390/cancers13164220] [Reference Citation Analysis]
378 Pellat A, Vaquero J, Fouassier L. Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology. Hepatology. 2017; Epub ahead of print. [PMID: 28671339 DOI: 10.1002/hep.29350] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
379 Mariotti V, Fiorotto R, Cadamuro M, Fabris L, Strazzabosco M. New insights on the role of vascular endothelial growth factor in biliary pathophysiology. JHEP Rep 2021;3:100251. [PMID: 34151244 DOI: 10.1016/j.jhepr.2021.100251] [Reference Citation Analysis]
380 Satriano L, Lewinska M, Rodrigues PM, Banales JM, Andersen JB. Metabolic rearrangements in primary liver cancers: cause and consequences. Nat Rev Gastroenterol Hepatol 2019;16:748-66. [PMID: 31666728 DOI: 10.1038/s41575-019-0217-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
381 Jiang ZM, Li HB, Chen SG. PIMREG, a Marker of Proliferation, Facilitates Aggressive Development of Cholangiocarcinoma Cells Partly Through Regulating Cell Cycle-Related Markers. Technol Cancer Res Treat 2020;19:1533033820979681. [PMID: 33356974 DOI: 10.1177/1533033820979681] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
382 García P, Lamarca A, Díaz J, Carrera E, Roa JC, On Behalf Of The European-Latin American Escalon Consortium. Current and New Biomarkers for Early Detection, Prognostic Stratification, and Management of Gallbladder Cancer Patients. Cancers (Basel) 2020;12:E3670. [PMID: 33297469 DOI: 10.3390/cancers12123670] [Reference Citation Analysis]
383 Yu H, Wang M, Wang Y, Yang J, Deng L, Bao W, He B, Lin Z, Chen Z, Chen K, Zhang B, Liu F, Yu Z, Ye L, Jin B, Chen G. The prognostic value of sarcopenia combined with preoperative fibrinogen-albumin ratio in patients with intrahepatic cholangiocarcinoma after surgery: A multicenter, prospective study. Cancer Med 2021;10:4768-80. [PMID: 34105304 DOI: 10.1002/cam4.4035] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
384 Roos E, Soer E, Klompmaker S, Meijer L, Besselink M, Giovannetti E, Heger M, Kazemier G, Klümpen H, Takkenberg R, Wilmink H, Würdinger T, Dijk F, van Gulik T, Verheij J, van de Vijver M. Crossing borders: A systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract. Critical Reviews in Oncology/Hematology 2019;140:8-16. [DOI: 10.1016/j.critrevonc.2019.05.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
385 Shiode Y, Kodama T, Shigeno S, Murai K, Tanaka S, Newberg JY, Kondo J, Kobayashi S, Yamada R, Hikita H, Sakamori R, Suemizu H, Tatsumi T, Eguchi H, Jenkins NA, Copeland NG, Takehara T. TNF receptor-related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF-κB-inducing kinase-mediated hepatocyte transdifferentiation. Hepatology 2022. [PMID: 34995376 DOI: 10.1002/hep.32317] [Reference Citation Analysis]
386 Kang MJ, Lim J, Han SS, Park HM, Kim SW, Won YJ, Park SJ. Impact of changes in the topographic classification of Klatskin tumor on incidence of intra- and extrahepatic bile duct cancer: A population-based national cancer registry study. J Hepatobiliary Pancreat Sci 2021. [PMID: 33615747 DOI: 10.1002/jhbp.916] [Reference Citation Analysis]
387 Rhee H, Ko JE, Chung T, Jee BA, Kwon SM, Nahm JH, Seok JY, Yoo JE, Choi J, Thorgeirsson SS, Andersen JB, Lee HS, Woo HG, Park YN. Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma. Liver Int 2018;38:113-24. [DOI: 10.1111/liv.13492] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
388 Nakamura Y, Taniguchi H, Ikeda M, Bando H, Kato K, Morizane C, Esaki T, Komatsu Y, Kawamoto Y, Takahashi N, Ueno M, Kagawa Y, Nishina T, Kato T, Yamamoto Y, Furuse J, Denda T, Kawakami H, Oki E, Nakajima T, Nishida N, Yamaguchi K, Yasui H, Goto M, Matsuhashi N, Ohtsubo K, Yamazaki K, Tsuji A, Okamoto W, Tsuchihara K, Yamanaka T, Miki I, Sakamoto Y, Ichiki H, Hata M, Yamashita R, Ohtsu A, Odegaard JI, Yoshino T. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med 2020;26:1859-64. [PMID: 33020649 DOI: 10.1038/s41591-020-1063-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 18.5] [Reference Citation Analysis]
389 Lamarca A, Barriuso J, Mcnamara MG, Valle JW. Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair. Cancer Treatment Reviews 2018;70:168-77. [DOI: 10.1016/j.ctrv.2018.09.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
390 Brivio S, Cadamuro M, Fabris L, Strazzabosco M. Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview. Gene Expr. 2018;18:31-50. [PMID: 29070148 DOI: 10.3727/105221617x15088670121925] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
391 Saensa-ard S, Leuangwattanawanit S, Senggunprai L, Namwat N, Kongpetch S, Chamgramol Y, Loilome W, Khansaard W, Jusakul A, Prawan A, Pairojkul C, Khantikeo N, Yongvanit P, Kukongviriyapan V. Establishment of cholangiocarcinoma cell lines from patients in the endemic area of liver fluke infection in Thailand. Tumour Biol 2017;39:101042831772592. [DOI: 10.1177/1010428317725925] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
392 Ilyas FZ, Beane JD, Pawlik TM. The State of Immunotherapy in Hepatobiliary Cancers. Cells 2021;10:2096. [PMID: 34440865 DOI: 10.3390/cells10082096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
393 Oneda E, Abu Hilal M, Zaniboni A. Biliary Tract Cancer: Current Medical Treatment Strategies.Cancers (Basel). 2020;12. [PMID: 32423017 DOI: 10.3390/cancers12051237] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
394 Kankeu Fonkoua LA, Serrano Uson Junior PL, Mody K, Mahipal A, Borad MJ, Roberts LR. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications. Expert Opin Ther Targets 2022. [PMID: 35034558 DOI: 10.1080/14728222.2022.2029412] [Reference Citation Analysis]
395 Arbelaiz A, Azkargorta M, Krawczyk M, Santos-laso A, Lapitz A, Perugorria MJ, Erice O, Gonzalez E, Jimenez-agüero R, Lacasta A, Ibarra C, Sanchez-campos A, Jimeno JP, Lammert F, Milkiewicz P, Marzioni M, Macias RI, Marin JJ, Patel T, Gores GJ, Martinez I, Elortza F, Falcon-perez JM, Bujanda L, Banales JM. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma: Arbelaiz et al. Hepatology 2017;66:1125-43. [DOI: 10.1002/hep.29291] [Cited by in Crossref: 116] [Cited by in F6Publishing: 118] [Article Influence: 23.2] [Reference Citation Analysis]
396 Lasagni A, Cadamuro M, Morana G, Fabris L, Strazzabosco M. Fibrocystic liver disease: novel concepts and translational perspectives. Transl Gastroenterol Hepatol 2021;6:26. [PMID: 33824930 DOI: 10.21037/tgh-2020-04] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
397 Brandi G, Tavolari S. Asbestos and Intrahepatic Cholangiocarcinoma. Cells 2020;9:E421. [PMID: 32059499 DOI: 10.3390/cells9020421] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
398 Labib PL, Goodchild G, Pereira SP. Molecular Pathogenesis of Cholangiocarcinoma. BMC Cancer. 2019;19:185. [PMID: 30819129 DOI: 10.1186/s12885-019-5391-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 59] [Article Influence: 16.7] [Reference Citation Analysis]
399 Wang SQ, Chai CX, Wang BR, Zhu F, Shang D, Li M. Liquid biopsy: Precise diagnosis and therapy for cholangiocarcinoma. World J Gastrointest Oncol 2022; 14(1): 362-365 [DOI: 10.4251/wjgo.v14.i1.362] [Reference Citation Analysis]
400 Mansini AP, Peixoto E, Jin S, Richard S, Gradilone SA. The Chemosensory Function of Primary Cilia Regulates Cholangiocyte Migration, Invasion, and Tumor Growth. Hepatology 2019;69:1582-98. [PMID: 30299561 DOI: 10.1002/hep.30308] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
401 Di Matteo S, Nevi L, Costantini D, Overi D, Carpino G, Safarikia S, Giulitti F, Napoletano C, Manzi E, De Rose AM, Melandro F, Bragazzi M, Berloco PB, Giuliante F, Grazi G, Giorgi A, Cardinale V, Adorini L, Gaudio E, Alvaro D. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma. PLoS One 2019;14:e0210077. [PMID: 30677052 DOI: 10.1371/journal.pone.0210077] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
402 Padthaisong S, Dokduang H, Yothaisong S, Techasen A, Namwat N, Yongvanit P, Khuntikeo N, Titapun A, Sangkhamanon S, Loilome W. Inhibitory effect of NVP-BKM120 on cholangiocarcinoma cell growth. Oncol Lett 2018;16:1627-33. [PMID: 30008846 DOI: 10.3892/ol.2018.8848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
403 Loeuillard E, Conboy CB, Gores GJ, Rizvi S. Immunobiology of cholangiocarcinoma. JHEP Rep. 2019;1:297-311. [PMID: 32039381 DOI: 10.1016/j.jhepr.2019.06.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
404 Wandee J, Prawan A, Senggunprai L, Kongpetch S, Kukongviriyapan V. Metformin sensitizes cholangiocarcinoma cell to cisplatin-induced cytotoxicity through oxidative stress mediated mitochondrial pathway. Life Sci 2019;217:155-63. [PMID: 30528773 DOI: 10.1016/j.lfs.2018.12.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
405 Kozaka K, Kobayashi S, Takamura H, Sato Y, Kitao A, Inoue D, Yoneda N, Tajima H, Kinuya S, Harada K, Ohta T, Koda W, Matsui O, Gabata T. Differences in 18F-FDG Uptake and Expression of Glucose Transporter Between 2 Distinct Subtypes of Mass-Forming Intrahepatic Cholangiocarcinomas. Clin Nucl Med 2020;45:e267-73. [PMID: 32366791 DOI: 10.1097/RLU.0000000000003055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
406 Nam AR, Jin MH, Park JE, Bang JH, Oh DY, Bang YJ. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer. Cancer Res Treat 2019;51:1167-79. [PMID: 30514066 DOI: 10.4143/crt.2018.526] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
407 Friedman JR, Richbart SD, Merritt JC, Perry HE, Brown KC, Akers AT, Nolan NA, Stevenson CD, Hurley JD, Miles SL, Tirona MT, Valentovic MA, Dasgupta P. Capsaicinoids enhance chemosensitivity to chemotherapeutic drugs. Adv Cancer Res 2019;144:263-98. [PMID: 31349900 DOI: 10.1016/bs.acr.2019.05.002] [Reference Citation Analysis]
408 Kitagawa K, Moriya K, Kaji K, Saikawa S, Sato S, Nishimura N, Namisaki T, Akahane T, Mitoro A, Yoshiji H. Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells. Int J Mol Sci 2020;21:E7588. [PMID: 33066548 DOI: 10.3390/ijms21207588] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
409 Peng Y, Meng G, Sheng X, Gao H. Transcriptome and DNA methylation analysis reveals molecular mechanisms underlying intrahepatic cholangiocarcinoma progression. J Cell Mol Med 2021. [PMID: 34013637 DOI: 10.1111/jcmm.16615] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
410 O'Rourke CJ, Munoz-Garrido P, Andersen JB. Molecular Targets in Cholangiocarcinoma. Hepatology 2021;73 Suppl 1:62-74. [PMID: 32304327 DOI: 10.1002/hep.31278] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
411 Jiang F, Ling X. The Advancement of Long Non-Coding RNAs in Cholangiocarcinoma Development. J Cancer. 2019;10:2407-2414. [PMID: 31258745 DOI: 10.7150/jca.32411] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
412 Zou H, Wang F, Zhou JJ, Liu X, He Q, Wang C, Zheng YW, Wen Y, Xiong L. Application of photodynamic therapy for liver malignancies. J Gastrointest Oncol 2020;11:431-42. [PMID: 32399283 DOI: 10.21037/jgo.2020.02.10] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
413 Hao J, Zhang Y, Huang X. Design and Development of a Disposable Superfine Catheter for Visual Examination of Bile Ducts and Related Animal Experiments. Front Surg 2022;9:877040. [DOI: 10.3389/fsurg.2022.877040] [Reference Citation Analysis]
414 Kato T, Murata D, Anders RA, Sesaki H, Iijima M. Nuclear PTEN and p53 suppress stress-induced liver cancer through distinct mechanisms. Biochem Biophys Res Commun 2021;549:83-90. [PMID: 33667713 DOI: 10.1016/j.bbrc.2021.02.093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
415 Tang Z, Yang Y, Zhang J, Fu W, Lin Y, Su G, Li Y, Meng W, Li X, Xie X. Quantitative Proteomic Analysis and Evaluation of the Potential Prognostic Biomarkers in Cholangiocarcinoma. J Cancer 2019;10:3985-99. [PMID: 31417643 DOI: 10.7150/jca.29354] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
416 Cadamuro M, Brivio S, Mertens J, Vismara M, Moncsek A, Milani C, Fingas C, Cristina Malerba M, Nardo G, Dall'Olmo L, Milani E, Mariotti V, Stecca T, Massani M, Spirli C, Fiorotto R, Indraccolo S, Strazzabosco M, Fabris L. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. J Hepatol. 2019;70:700-709. [PMID: 30553841 DOI: 10.1016/j.jhep.2018.12.004] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
417 Huguet JM, Lobo M, Labrador JM, Boix C, Albert C, Ferrer-Barceló L, Durá AB, Suárez P, Iranzo I, Gil-Raga M, Burgos CB, Sempere J. Diagnostic-therapeutic management of bile duct cancer. World J Clin Cases 2019; 7(14): 1732-1752 [PMID: 31417920 DOI: 10.12998/wjcc.v7.i14.1732] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
418 Bourien H, Lamarca A, McNamara MG, Hubner RA, Valle JW, Edeline J. Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials. Expert Opin Investig Drugs 2021;30:975-83. [PMID: 34420429 DOI: 10.1080/13543784.2021.1964470] [Reference Citation Analysis]
419 Ueno M, Morizane C, Furukawa M, Sakai D, Komatsu Y, Nakai Y, Tsuda M, Ozaka M, Mizuno N, Muto M, Fukutomi A, Ikeda M, Tsuji A, Katanuma A, Moriwaki T, Kajiwara T, Ishii H, Negoro Y, Shimizu S, Nemoto N, Kobayashi S, Makino K, Furuse J. A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy. Cancer Med 2021;10:2088-99. [PMID: 33635605 DOI: 10.1002/cam4.3813] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
420 Song W, Miao DL, Chen L. Comprehensive analysis of long noncoding RNA-associated competing endogenous RNA network in cholangiocarcinoma. Biochem Biophys Res Commun 2018;506:1004-12. [PMID: 30404735 DOI: 10.1016/j.bbrc.2018.10.186] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
421 Vicent S, Lieshout R, Saborowski A, Verstegen MMA, Raggi C, Recalcati S, Invernizzi P, van der Laan LJW, Alvaro D, Calvisi DF, Cardinale V. Experimental models to unravel the molecular pathogenesis, cell of origin and stem cell properties of cholangiocarcinoma. Liver Int 2019;39 Suppl 1:79-97. [PMID: 30851232 DOI: 10.1111/liv.14094] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
422 Rațiu I, Lupușoru R, Lungeanu D, Popescu A, Sporea I, Goldiș A, Dănilă M, Miuțescu B, Moga T, Barbulescu A, Tăban S, Dema A, Șirli R. Diagnosis of malignant biliary obstruction: pondering over the ERCP, MRCP and histology. J Int Med Res 2022;50:3000605221076924. [PMID: 35170356 DOI: 10.1177/03000605221076924] [Reference Citation Analysis]
423 Qin X, Song Y. Bioinformatics Analysis Identifies the Estrogen Receptor 1 (ESR1) Gene and hsa-miR-26a-5p as Potential Prognostic Biomarkers in Patients with Intrahepatic Cholangiocarcinoma. Med Sci Monit 2020;26:e921815. [PMID: 32435051 DOI: 10.12659/MSM.921815] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
424 Rahnemai-Azar AA, Weisbrod A, Dillhoff M, Schmidt C, Pawlik TM. Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis. Surg Oncol. 2017;26:125-137. [PMID: 28577718 DOI: 10.1016/j.suronc.2016.12.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
425 Vedeld HM, Folseraas T, Lind GE. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis - The promise of DNA methylation and molecular biomarkers.JHEP Rep. 2020;2:100143. [PMID: 32939446 DOI: 10.1016/j.jhepr.2020.100143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
426 Jung IH, Kim DH, Yoo DK, Baek SY, Jeong SH, Jung DE, Park SW, Chung YY. In Vivo Study of Natural Killer (NK) Cell Cytotoxicity Against Cholangiocarcinoma in a Nude Mouse Model. In Vivo. 2018;32:771-781. [PMID: 29936458 DOI: 10.21873/invivo.11307] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
427 Lee S, Kim JH, Lee JH, Zen Y, Han JK. Imaging Monitoring of Kupffer Cell Function and Hepatic Oxygen Saturation in Preneoplastic Changes During Cholangiocarcinogenesis. Sci Rep 2017;7:14203. [PMID: 29079853 DOI: 10.1038/s41598-017-14218-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
428 Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, Nellore V, Kongpetch S, Ng AWT, Ng LM, Choo SP, Myint SS, Thanan R, Nagarajan S, Lim WK, Ng CCY, Boot A, Liu M, Ong CK, Rajasegaran V, Lie S, Lim AST, Lim TH, Tan J, Loh JL, McPherson JR, Khuntikeo N, Bhudhisawasdi V, Yongvanit P, Wongkham S, Totoki Y, Nakamura H, Arai Y, Yamasaki S, Chow PK, Chung AYF, Ooi LLPJ, Lim KH, Dima S, Duda DG, Popescu I, Broet P, Hsieh SY, Yu MC, Scarpa A, Lai J, Luo DX, Carvalho AL, Vettore AL, Rhee H, Park YN, Alexandrov LB, Gordân R, Rozen SG, Shibata T, Pairojkul C, Teh BT, Tan P. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. Cancer Discov 2017;7:1116-35. [PMID: 28667006 DOI: 10.1158/2159-8290.CD-17-0368] [Cited by in Crossref: 266] [Cited by in F6Publishing: 169] [Article Influence: 53.2] [Reference Citation Analysis]
429 Mehta R, Wood AC, Yu J, Kim R. Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies. Expert Opin Investig Drugs 2021;30:451-61. [PMID: 33660569 DOI: 10.1080/13543784.2021.1898586] [Reference Citation Analysis]
430 Filippi R, Leone F, Fornaro L, Aprile G, Casadei-Gardini A, Silvestris N, Palloni A, Satolli MA, Scartozzi M, Russano M, Lutrino SE, Lombardi P, Frega G, Garattini SK, Vivaldi C, Spadi R, Giulia O, Fenocchio E, Brunetti O, Aglietta M, Brandi G. Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. J Chemother 2021;:1-10. [PMID: 34313188 DOI: 10.1080/1120009X.2021.1953887] [Reference Citation Analysis]
431 Nabeshima T, Hamada S, Taguchi K, Tanaka Y, Matsumoto R, Yamamoto M, Masamune A. Keap1 deletion accelerates mutant K-ras/p53-driven cholangiocarcinoma. Am J Physiol Gastrointest Liver Physiol 2020;318:G419-27. [PMID: 31961719 DOI: 10.1152/ajpgi.00296.2019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
432 Wu J, Sheng J, Qin H, Cui M, Yang Y, Zhang X. The Application Progress of Patient-Derived Tumor Xenograft Models After Cholangiocarcinoma Surgeries. Front Oncol 2021;11:628636. [PMID: 34367944 DOI: 10.3389/fonc.2021.628636] [Reference Citation Analysis]
433 Cadamuro M, Lasagni A, Lamarca A, Fouassier L, Guido M, Sarcognato S, Gringeri E, Cillo U, Strazzabosco M, Marin JJ, Banales JM, Fabris L. Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. Expert Opin Investig Drugs 2021;30:377-88. [PMID: 33622120 DOI: 10.1080/13543784.2021.1880564] [Reference Citation Analysis]
434 Wang D, Guo H, Yang H, Wang D, Gao P, Wei W. Pterostilbene, An Active Constituent of Blueberries, Suppresses Proliferation Potential of Human Cholangiocarcinoma via Enhancing the Autophagic Flux. Front Pharmacol 2019;10:1238. [PMID: 31695612 DOI: 10.3389/fphar.2019.01238] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
435 Cavalloni G, Peraldo-Neia C, Massa A, Bergamini C, Trentini A, De Rosa G, Daniele L, Ciccosanti F, Cervellati C, Leone F, Aglietta M. Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients. BMC Cancer 2021;21:865. [PMID: 34320944 DOI: 10.1186/s12885-021-08576-z] [Reference Citation Analysis]
436 Fiz F, Masci C, Costa G, Sollini M, Chiti A, Ieva F, Torzilli G, Viganò L. PET/CT-based radiomics of mass-forming intrahepatic cholangiocarcinoma improves prediction of pathology data and survival. Eur J Nucl Med Mol Imaging. [DOI: 10.1007/s00259-022-05765-1] [Reference Citation Analysis]
437 Kittirat Y, Phetcharaburanin J, Promraksa B, Kulthawatsiri T, Wangwiwatsin A, Klanrit P, Sangkhamanon S, Jarearnrat A, Thongchot S, Mahalapbutr P, Loilome W, Saya H, Namwat N. Lipidomic Analyses Uncover Apoptotic and Inhibitory Effects of Pyrvinium Pamoate on Cholangiocarcinoma Cells via Mitochondrial Membrane Potential Dysfunction. Front Public Health 2021;9:766455. [DOI: 10.3389/fpubh.2021.766455] [Reference Citation Analysis]
438 Wacker F, Dewald C. [Local and locoregional treatment of intrahepatic cholangiocarcinoma]. Radiologe 2022. [PMID: 34981129 DOI: 10.1007/s00117-021-00946-9] [Reference Citation Analysis]
439 Collins K, Newcomb PH, Cartun RW, Ligato S. Utility and Limitations of Albumin mRNA In Situ Hybridization Detection in the Diagnosis of Hepatobiliary Lesions and Metastatic Carcinoma to the Liver. Appl Immunohistochem Mol Morphol 2021;29:180-7. [PMID: 33208670 DOI: 10.1097/PAI.0000000000000885] [Reference Citation Analysis]
440 Rizzo A, Frega G, Ricci AD, Palloni A, Abbati F, DE Lorenzo S, Deserti M, Tavolari S, Brandi G. Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-analysis. In Vivo 2020;34:479-88. [PMID: 32111744 DOI: 10.21873/invivo.11798] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
441 Leone V, Ali A, Weber A, Tschaharganeh DF, Heikenwalder M. Liver Inflammation and Hepatobiliary Cancers. Trends Cancer 2021;7:606-23. [PMID: 33674229 DOI: 10.1016/j.trecan.2021.01.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
442 Lorenzo N, Sabina DM, Guido C, Ilaria Grazia Z, Samira S, Valeria A, Daniele C, Diletta O, Antonella G, Marco M, Daniela B, Valerio P, Andrea O, Agostino Maria R, Fabio M, Maria Consiglia B, Jessica F, Sara M, Gian Luca G, Pierluigi Benedetti P, Paquale Bartomeo B, Felice G, Vincenzo C, Pietro I, Giuseppina C, Eugenio G, Domenico A. DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma. Hepatology 2021;73:144-59. [PMID: 32978808 DOI: 10.1002/hep.31571] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
443 Li J, Wei Q, Wu X, Sima J, Xu Q, Wu M, Wang F, Mou H, Hu H, Zhao J, Li D, Hu J, Zhang L, Zhu X, Chen L, Luo C, Yan J, He J, Ma Y, Shao Y, Wu W, Ying J. Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response. Clin Transl Med 2020;10:e118. [PMID: 32898339 DOI: 10.1002/ctm2.118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
444 Liu X, Yao J, Song L, Zhang S, Huang T, Li Y. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade. J Immunother Cancer 2019;7:204. [PMID: 31383016 DOI: 10.1186/s40425-019-0692-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
445 Cadamuro M, Brivio S, Spirli C, Joplin RE, Strazzabosco M, Fabris L. Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma. Int J Mol Sci 2017;18:E149. [PMID: 28098760 DOI: 10.3390/ijms18010149] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
446 Saranaruk P, Kariya R, Sittithumcharee G, Boueroy P, Boonmars T, Sawanyawisuth K, Wongkham C, Wongkham S, Okada S, Vaeteewoottacharn K. Chromomycin A3 suppresses cholangiocarcinoma growth by induction of S phase cell cycle arrest and suppression of Sp1‑related anti‑apoptotic proteins. Int J Mol Med 2020;45:1005-16. [PMID: 32124934 DOI: 10.3892/ijmm.2020.4482] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
447 Arteta AA, Milanes-Yearsley M, Cardona-Castro N. Cholangiocyte derived carcinomas and local microbiota. J Hepatobiliary Pancreat Sci 2020. [PMID: 32902144 DOI: 10.1002/jhbp.826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
448 Sinniah RS, Shapses MS, Ahmed MU, Babiker H, Chandana SR. Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1. Expert Opin Investig Drugs 2021;30:1047-56. [PMID: 34579607 DOI: 10.1080/13543784.2021.1985461] [Reference Citation Analysis]
449 Roos FJM, van Tienderen GS, Wu H, Bordeu I, Vinke D, Albarinos LM, Monfils K, Niesten S, Smits R, Willemse J, Rosmark O, Westergren-Thorsson G, Kunz DJ, de Wit M, French PJ, Vallier L, IJzermans JNM, Bartfai R, Marks H, Simons BD, van Royen ME, Verstegen MMA, van der Laan LJW. Human branching cholangiocyte organoids recapitulate functional bile duct formation. Cell Stem Cell 2022;29:776-794.e13. [PMID: 35523140 DOI: 10.1016/j.stem.2022.04.011] [Reference Citation Analysis]
450 Boilève A, Hilmi M, Smolenschi C, Ducreux M, Hollebecque A, Malka D. Immunotherapy in Advanced Biliary Tract Cancers. Cancers (Basel) 2021;13:1569. [PMID: 33805461 DOI: 10.3390/cancers13071569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
451 Hormati A, Jafari S, Jabbari A, Pezeshki Modares M, Afifian M, Abasi A, Ahmadpour S, Sharifi AR. Comparison between Brush Cytology and Forceps Biopsy under Fluoroscopic Guidance for the Diagnosis of Proximal Cholangiocarcinoma. Middle East J Dig Dis 2020;12:246-51. [PMID: 33564381 DOI: 10.34172/mejdd.2020.189] [Reference Citation Analysis]
452 Goeppert B, Stichel D, Toth R, Fritzsche S, Loeffler MA, Schlitter AM, Neumann O, Assenov Y, Vogel MN, Mehrabi A, Hoffmann K, Köhler B, Springfeld C, Weichenhan D, Plass C, Esposito I, Schirmacher P, von Deimling A, Roessler S. Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis. Gut 2021:gutjnl-2020-322983. [PMID: 33468537 DOI: 10.1136/gutjnl-2020-322983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
453 Ney A, Garcia-Sampedro A, Goodchild G, Acedo P, Fusai G, Pereira SP. Biliary Strictures and Cholangiocarcinoma - Untangling a Diagnostic Conundrum. Front Oncol 2021;11:699401. [PMID: 34660269 DOI: 10.3389/fonc.2021.699401] [Reference Citation Analysis]
454 Capobianco I, Rolinger J, Nadalin S. Resection for Klatskin tumors: technical complexities and results. Transl Gastroenterol Hepatol. 2018;3:69. [PMID: 30363698 DOI: 10.21037/tgh.2018.09.01] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
455 Lagenfelt H, Blomstrand H, Elander NO. Real-World Evidence on Palliative Gemcitabine and Oxaliplatin (GemOx) Combination Chemotherapy in Advanced Biliary Tract Cancer. Cancers (Basel) 2021;13:3507. [PMID: 34298723 DOI: 10.3390/cancers13143507] [Reference Citation Analysis]
456 Kim-Fuchs C, Candinas D, Lachenmayer A. The Role of Conventional and Stereotactic Microwave Ablation for Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2963. [PMID: 34279447 DOI: 10.3390/jcm10132963] [Reference Citation Analysis]
457 Ma C, Zhang Q, Greten TF. MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target. Cell Immunol 2021;361:104295. [PMID: 33508529 DOI: 10.1016/j.cellimm.2021.104295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
458 Fabris L, Cadamuro M, Cagnin S, Strazzabosco M, Gores GJ. Liver Matrix in Benign and Malignant Biliary Tract Disease. Semin Liver Dis 2020;40:282-97. [PMID: 32162285 DOI: 10.1055/s-0040-1705109] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
459 Hang H, Jeong S, Sha M, Kong D, Xi Z, Tong Y, Xia Q. Cholangiocarcinoma: anatomical location-dependent clinical, prognostic, and genetic disparities. Ann Transl Med 2019;7:744. [PMID: 32042760 DOI: 10.21037/atm.2019.12.37] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
460 Cannito S, Milani C, Cappon A, Parola M, Strazzabosco M, Cadamuro M. Fibroinflammatory Liver Injuries as Preneoplastic Condition in Cholangiopathies. Int J Mol Sci. 2018;19. [PMID: 30518128 DOI: 10.3390/ijms19123875] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
461 Pittman ME, Yantiss RK. Frozen Sections of the Liver. Surg Pathol Clin 2018;11:453-66. [PMID: 29751885 DOI: 10.1016/j.path.2018.02.012] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
462 Affo S, Yu LX, Schwabe RF. The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer. Annu Rev Pathol 2017;12:153-86. [PMID: 27959632 DOI: 10.1146/annurev-pathol-052016-100322] [Cited by in Crossref: 183] [Cited by in F6Publishing: 189] [Article Influence: 30.5] [Reference Citation Analysis]
463 Walter D, Ferstl P, Waidmann O, Trojan J, Hartmann S, Schnitzbauer AA, Zeuzem S, Kraywinkel K. Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification. Liver Int 2019;39:316-23. [PMID: 30176117 DOI: 10.1111/liv.13954] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
464 Goeppert B. [Biliary tract cancers : Molecular characterization and identification of novel prognostic markers]. Pathologe 2017;38:192-7. [PMID: 29063951 DOI: 10.1007/s00292-017-0359-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
465 Dechêne A, Kasper S, Olivecrona H, Schirra J, Trojan J. Photochemical internalization and gemcitabine combined with first-line chemotherapy in perihilar cholangiocarcinoma: observations in three patients. Endosc Int Open 2020;8:E1878-83. [PMID: 33269324 DOI: 10.1055/a-1276-6366] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
466 Ritz T, Krenkel O, Tacke F. Dynamic plasticity of macrophage functions in diseased liver. Cell Immunol 2018;330:175-82. [PMID: 29454647 DOI: 10.1016/j.cellimm.2017.12.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
467 Bartolini I, Risaliti M, Tucci R, Muiesan P, Ringressi MN, Taddei A, Amedei A. Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment. World J Gastrointest Oncol 2021; 13(11): 1616-1631 [PMID: 34853639 DOI: 10.4251/wjgo.v13.i11.1616] [Reference Citation Analysis]
468 Vaquero J, Aoudjehane L, Fouassier L. Cancer-associated fibroblasts in cholangiocarcinoma. Curr Opin Gastroenterol 2020;36:63-9. [PMID: 31934895 DOI: 10.1097/MOG.0000000000000609] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
469 Baiocchi L, Lenci I, Milana M, Kennedy L, Sato K, Zhang W, Ekser B, Ceci L, Meadows V, Glaser S, Alpini G, Francis H. Cyclic AMP Signaling in Biliary Proliferation: A Possible Target for Cholangiocarcinoma Treatment? Cells 2021;10:1692. [PMID: 34359861 DOI: 10.3390/cells10071692] [Reference Citation Analysis]
470 Pollicino T, Musolino C, Saitta C, Tripodi G, Lanza M, Raffa G, Tocco FCD, Raggi C, Bragazzi MC, Barbera A, Navarra G, Invernizzi P, Alvaro D, Raimondo G. Free episomal and integrated HBV DNA in HBsAg-negative patients with intrahepatic cholangiocarcinoma. Oncotarget. 2019;10:3931-3938. [PMID: 31231470 DOI: 10.18632/oncotarget.27002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
471 Nicolás-Boluda A, Vaquero J, Laurent G, Renault G, Bazzi R, Donnadieu E, Roux S, Fouassier L, Gazeau F. Photothermal Depletion of Cancer-Associated Fibroblasts Normalizes Tumor Stiffness in Desmoplastic Cholangiocarcinoma. ACS Nano 2020;14:5738-53. [PMID: 32338871 DOI: 10.1021/acsnano.0c00417] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
472 Yang T, Deng Z, Xu L, Li X, Yang T, Qian Y, Lu Y, Tian L, Yao W, Wang J. Macrophages-aPKCɩ-CCL5 Feedback Loop Modulates the Progression and Chemoresistance in Cholangiocarcinoma. J Exp Clin Cancer Res 2022;41:23. [PMID: 35033156 DOI: 10.1186/s13046-021-02235-8] [Reference Citation Analysis]
473 Bui KC, Barat S, Chen X, Bozko P, Scholta T, Nguyen MLT, Bhuria V, Xing J, Nguyen LT, Le HS, Velavan TP, Sipos B, Wilkens L, Malek NP, Plentz RR. Silencing of Kangai 1 C-terminal interacting tetraspanin suppresses progression of cholangiocarcinoma. Exp Cell Res 2018;364:59-67. [PMID: 29366806 DOI: 10.1016/j.yexcr.2018.01.028] [Reference Citation Analysis]
474 Vaeteewoottacharn K, Pairojkul C, Kariya R, Muisuk K, Imtawil K, Chamgramol Y, Bhudhisawasdi V, Khuntikeo N, Pugkhem A, Saeseow OT, Silsirivanit A, Wongkham C, Wongkham S, Okada S. Establishment of Highly Transplantable Cholangiocarcinoma Cell Lines from a Patient-Derived Xenograft Mouse Model. Cells 2019;8:E496. [PMID: 31126020 DOI: 10.3390/cells8050496] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
475 Lapitz A, Arbelaiz A, O'Rourke CJ, Lavin JL, Casta A, Ibarra C, Jimeno JP, Santos-Laso A, Izquierdo-Sanchez L, Krawczyk M, Perugorria MJ, Jimenez-Aguero R, Sanchez-Campos A, Riaño I, Gónzalez E, Lammert F, Marzioni M, Macias RIR, Marin JJG, Karlsen TH, Bujanda L, Falcón-Pérez JM, Andersen JB, Aransay AM, Rodrigues PM, Banales JM. Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis. Cells 2020;9:E721. [PMID: 32183400 DOI: 10.3390/cells9030721] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
476 Marin JJG, Sanchon-Sanchez P, Cives-Losada C, Del Carmen S, González-Santiago JM, Monte MJ, Macias RIR. Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance. Cancers (Basel) 2021;13:2358. [PMID: 34068398 DOI: 10.3390/cancers13102358] [Reference Citation Analysis]
477 Rizzo A, Ricci AD, Bonucci C, Tober N, Palloni A, Frega G, Brandi G. Experimental HER2- targeted therapies for biliary tract cancer. Expert Opin Investig Drugs 2021;30:389-99. [PMID: 33218269 DOI: 10.1080/13543784.2021.1854724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
478 Ni Q, Zhang H, Shi X, Li X. Exosomal microRNA-23a-3p contributes to the progression of cholangiocarcinoma by interaction with Dynamin3. Bioengineered 2022;13:6208-21. [PMID: 35200104 DOI: 10.1080/21655979.2022.2037249] [Reference Citation Analysis]
479 Urtasun N, Boces-Pascual C, Boix L, Bruix J, Pastor-Anglada M, Pérez-Torras S. Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma. Oncotarget 2017;8:90185-96. [PMID: 29163820 DOI: 10.18632/oncotarget.21624] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
480 Cigliano A, Chen X, Calvisi DF. Current challenges to underpinning the genetic basis for cholangiocarcinoma. Expert Rev Gastroenterol Hepatol 2021;15:511-26. [PMID: 33888034 DOI: 10.1080/17474124.2021.1915128] [Reference Citation Analysis]
481 Chang YC, Chen MH, Yeh CN, Hsiao M. Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma. Biomolecules 2020;10:E1377. [PMID: 32998289 DOI: 10.3390/biom10101377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
482 Boilève A, Hilmi M, Delaye M, Tijeras-Raballand A, Neuzillet C. Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice? Cancers (Basel) 2021;13:2708. [PMID: 34070929 DOI: 10.3390/cancers13112708] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
483 Anichini G, Carrassa L, Stecca B, Marra F, Raggi C. The Role of the Hedgehog Pathway in Cholangiocarcinoma. Cancers (Basel) 2021;13:4774. [PMID: 34638259 DOI: 10.3390/cancers13194774] [Reference Citation Analysis]
484 Wang W, Fei Y, Liu J, Yu T, Tang J, Wei F. Laparoscopic surgery and robotic surgery for hilar cholangiocarcinoma: an updated systematic review. ANZ J Surg 2021;91:42-8. [PMID: 32395906 DOI: 10.1111/ans.15948] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
485 Ono K, Takigawa S, Yamada K. L-Glucose: Another Path to Cancer Cells. Cancers (Basel) 2020;12:E850. [PMID: 32244695 DOI: 10.3390/cancers12040850] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
486 Kim JW, Lee KH, Kim JW, Suh KJ, Nam AR, Bang JH, Jin MH, Oh KS, Kim JM, Kim TY, Oh DY. The prognostic role of soluble transforming growth factor-β and its correlation with soluble programmed death-ligand 1 in biliary tract cancer. Liver Int 2021;41:388-95. [PMID: 32780918 DOI: 10.1111/liv.14636] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
487 de Jong DM, Fritzsche JA, Audhoe AS, Yi SSL, Bruno MJ, Voermans RP, van Driel LMJW. Comparison of Intraductal RFA Plus Stent versus Stent-Only Treatment for Unresectable Perihilar Cholangiocarcinoma—A Systematic Review and Meta-Analysis. Cancers 2022;14:2079. [DOI: 10.3390/cancers14092079] [Reference Citation Analysis]
488 Zheng Y, Wang S, Cai J, Ke A, Fan J. The progress of immune checkpoint therapy in primary liver cancer. Biochim Biophys Acta Rev Cancer 2021;1876:188638. [PMID: 34688805 DOI: 10.1016/j.bbcan.2021.188638] [Reference Citation Analysis]
489 Bijlsma MF, Sadanandam A, Tan P, Vermeulen L. Molecular subtypes in cancers of the gastrointestinal tract. Nat Rev Gastroenterol Hepatol 2017;14:333-42. [PMID: 28400627 DOI: 10.1038/nrgastro.2017.33] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 12.0] [Reference Citation Analysis]
490 Vedeld HM, Goel A, Lind GE. Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives. Semin Cancer Biol. 2018;51:36-49. [PMID: 29253542 DOI: 10.1016/j.semcancer.2017.12.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
491 Ku D, Tang R, Pang T, Pleass H, Richardson A, Yuen L, Lam V. Survival outcomes of hepatic resections in Bismuth-Corlette type IV cholangiocarcinoma. ANZ J Surg 2020;90:1604-14. [PMID: 31840387 DOI: 10.1111/ans.15531] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
492 Cheng Z, Lei Z, Shen F. Coming of a precision era of the staging systems for intrahepatic cholangiocarcinoma? Cancer Lett 2019;460:10-7. [PMID: 31212000 DOI: 10.1016/j.canlet.2019.114426] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
493 Chaidee A, Onsurathum S, Intuyod K, Pannangpetch P, Pongchaiyakul C, Pinlaor P, Pairojkul C, Ittiprasert W, Cochran CJ, Mann VH, Brindley PJ, Pinlaor S. Co-occurrence of opisthorchiasis and diabetes exacerbates morbidity of the hepatobiliary tract disease. PLoS Negl Trop Dis 2018;12:e0006611. [PMID: 29953446 DOI: 10.1371/journal.pntd.0006611] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
494 Zhang Z, Wang Z, Huang Y. A Bibliometric Analysis of 8,276 Publications During the Past 25 Years on Cholangiocarcinoma by Machine Learning. Front Oncol 2021;11:687904. [PMID: 34557406 DOI: 10.3389/fonc.2021.687904] [Reference Citation Analysis]
495 Roos E, Strijker M, Franken LC, Busch OR, van Hooft JE, Klümpen HJ, van Laarhoven HW, Wilmink JW, Verheij J, van Gulik TM, Besselink MG. Comparison of short- and long-term outcomes between anatomical subtypes of resected biliary tract cancer in a Western high-volume center. HPB (Oxford) 2020;22:405-14. [PMID: 31494056 DOI: 10.1016/j.hpb.2019.07.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
496 Hayashi H, Baba H. New era with the genetic assessment for biliary tree cancers beyond the anatomical assessment alone. Ann Transl Med 2020;8:732. [PMID: 32647657 DOI: 10.21037/atm.2020.03.206] [Reference Citation Analysis]
497 Yan X, Wang P, Zhu Z, Ning Z, Xu L, Zhuang L, Sheng J, Meng Z. Site-specific metastases of intrahepatic cholangiocarcinoma and its impact on survival: a population-based study. Future Oncol. 2019;15:2125-2137. [PMID: 31161810 DOI: 10.2217/fon-2018-0846] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
498 Rizzo A, Brandi G. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. Expert Review of Gastroenterology & Hepatology 2021;15:483-5. [DOI: 10.1080/17474124.2021.1864325] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
499 Chaisaingmongkol J, Budhu A, Dang H, Rabibhadana S, Pupacdi B, Kwon SM, Forgues M, Pomyen Y, Bhudhisawasdi V, Lertprasertsuke N, Chotirosniramit A, Pairojkul C, Auewarakul CU, Sricharunrat T, Phornphutkul K, Sangrajrang S, Cam M, He P, Hewitt SM, Ylaya K, Wu X, Andersen JB, Thorgeirsson SS, Waterfall JJ, Zhu YJ, Walling J, Stevenson HS, Edelman D, Meltzer PS, Loffredo CA, Hama N, Shibata T, Wiltrout RH, Harris CC, Mahidol C, Ruchirawat M, Wang XW; TIGER-LC Consortium. Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma. Cancer Cell. 2017;32:57-70.e3. [PMID: 28648284 DOI: 10.1016/j.ccell.2017.05.009] [Cited by in Crossref: 144] [Cited by in F6Publishing: 142] [Article Influence: 28.8] [Reference Citation Analysis]
500 Zhou T, Zhu J, Shang D, Chai C, Li Y, Sun H, Li Y, Gao M, Li M. Mitochondria-anchoring and AIE-active photosensitizer for self-monitored cholangiocarcinoma therapy. Mater Chem Front 2020;4:3201-8. [DOI: 10.1039/d0qm00503g] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
501 Kingham TP, Aveson VG, Wei AC, Castellanos JA, Allen PJ, Nussbaum DP, Hu Y, D'Angelica MI. Surgical management of biliary malignancy. Curr Probl Surg 2021;58:100854. [PMID: 33531120 DOI: 10.1016/j.cpsurg.2020.100854] [Reference Citation Analysis]
502 Solomon BL, Garrido-Laguna I. Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. Future Oncol 2018;14:947-62. [PMID: 29542354 DOI: 10.2217/fon-2017-0597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
503 Möhring C, Feder J, Mohr RU, Sadeghlar F, Bartels A, Mahn R, Zhou T, Marinova M, Feldmann G, Brossart P, von Websky M, Matthaei H, Manekeller S, Glowka T, Kalff JC, Weismüller TJ, Strassburg CP, Gonzalez-Carmona MA. First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis. Front Oncol 2021;11:717397. [PMID: 34858809 DOI: 10.3389/fonc.2021.717397] [Reference Citation Analysis]
504 Hu J, Wang YN, Song DJ, Tan JP, Cao Y, Fan J, Wang Z, Zhou J. A High-Accuracy Model Based on Plasma miRNAs Diagnoses Intrahepatic Cholangiocarcinoma: A Single Center with 1001 Samples. Diagnostics (Basel) 2021;11:610. [PMID: 33805513 DOI: 10.3390/diagnostics11040610] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
505 Losurdo G, Gravina AG, Maroni L, Gabrieletto EM, Ianiro G, Ferrarese A; Young Investigator group of SIGE, the Italian Society of Gastroenterology. Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. Dig Liver Dis 2021:S1590-8658(21)00455-2. [PMID: 34509394 DOI: 10.1016/j.dld.2021.08.008] [Reference Citation Analysis]
506 Branchi V, Esser L, Boden C, Jafari A, Henn J, Lingohr P, Gonzalez-Carmona MA, Schmitz M, Weismüller TJ, Strassburg CP, Manekeller S, Kristiansen G, Kalff JC, Matthaei H, Toma MI. A Combined TLR7/TLR9/GATA3 Score Can Predict Prognosis in Biliary Tract Cancer. Diagnostics (Basel) 2021;11:1597. [PMID: 34573939 DOI: 10.3390/diagnostics11091597] [Reference Citation Analysis]
507 Sarcognato S, Sacchi D, Fassan M, Fabris L, Cadamuro M, Zanus G, Cataldo I, Capelli P, Baciorri F, Cacciatore M, Guido M. Cholangiocarcinoma. Pathologica 2021;113:158-69. [PMID: 34294934 DOI: 10.32074/1591-951X-252] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
508 Ren H, Luo M, Chen J, Zhou Y, Li X, Zhan Y, Shen D, Chen B. Identification of TPD52 and DNAJB1 as two novel bile biomarkers for cholangiocarcinoma by iTRAQ‑based quantitative proteomics analysis. Oncol Rep 2019;42:2622-34. [PMID: 31661142 DOI: 10.3892/or.2019.7387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
509 Guest RV, Boulter L, Dwyer BJ, Forbes SJ. Understanding liver regeneration to bring new insights to the mechanisms driving cholangiocarcinoma. NPJ Regen Med 2017;2:13. [PMID: 29302349 DOI: 10.1038/s41536-017-0018-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
510 Cornillet M, Jansson H, Schaffer M, Hertwig L, Berglin L, Zimmer CL, Johansson H, Ellis E, Isaksson B, Gonzalez-Galarza FF, Middleton D, Malmberg KJ, Sparrelid E, Björkström NK. Imbalance of Genes Encoding Natural Killer Immunoglobulin-Like Receptors and Human Leukocyte Antigen in Patients With Biliary Cancer. Gastroenterology 2019;157:1067-1080.e9. [PMID: 31229495 DOI: 10.1053/j.gastro.2019.06.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
511 Choi IS, Kim KH, Lee JH, Suh KJ, Kim JW, Park JH, Kim YJ, Kim JS, Kim JH, Kim JW. A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. Eur J Cancer 2021;154:288-95. [PMID: 34303267 DOI: 10.1016/j.ejca.2021.06.019] [Reference Citation Analysis]
512 Joo I, Lee JM, Yoon JH. Imaging Diagnosis of Intrahepatic and Perihilar Cholangiocarcinoma: Recent Advances and Challenges. Radiology 2018;288:7-13. [DOI: 10.1148/radiol.2018171187] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 12.3] [Reference Citation Analysis]
513 Banales JM, Iñarrairaegui M, Arbelaiz A, Milkiewicz P, Muntané J, Muñoz-Bellvis L, La Casta A, Gonzalez LM, Arretxe E, Alonso C, Martínez-Arranz I, Lapitz A, Santos-Laso A, Avila MA, Martínez-Chantar ML, Bujanda L, Marin JJG, Sangro B, Macias RIR. Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. Hepatology 2019;70:547-62. [PMID: 30325540 DOI: 10.1002/hep.30319] [Cited by in Crossref: 35] [Cited by in F6Publishing: 42] [Article Influence: 11.7] [Reference Citation Analysis]
514 Baiocchi L, Sato K, Ekser B, Kennedy L, Francis H, Ceci L, Lenci I, Alvaro D, Franchitto A, Onori P, Gaudio E, Wu C, Chakraborty S, Glaser S, Alpini G. Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy. Expert Opin Investig Drugs 2021;30:365-75. [PMID: 33226854 DOI: 10.1080/13543784.2021.1854725] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
515 Khoontawad J, Intuyod K, Rucksaken R, Hongsrichan N, Pairojkul C, Pinlaor P, Boonmars T, Wongkham C, Jones A, Plieskatt J, Potriquet J, Bethony JM, Mulvenna J, Pinlaor S. Discovering proteins for chemoprevention and chemotherapy by curcumin in liver fluke infection-induced bile duct cancer. PLoS One 2018;13:e0207405. [PMID: 30440021 DOI: 10.1371/journal.pone.0207405] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
516 Mancinelli R, Mammola C, Sferra R, Pompili S, Vetuschi A, Pannarale L. Role of the Angiogenic Factors in Cholangiocarcinoma. Applied Sciences 2019;9:1393. [DOI: 10.3390/app9071393] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
517 Wang XY, Zhu WW, Wang Z, Huang JB, Wang SH, Bai FM, Li TE, Zhu Y, Zhao J, Yang X, Lu L, Zhang JB, Jia HL, Dong QZ, Chen JH, Andersen JB, Ye D, Qin LX. Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities. Theranostics 2022;12:260-76. [PMID: 34987644 DOI: 10.7150/thno.63417] [Reference Citation Analysis]
518 Klinhom-On N, Seubwai W, Sawanyawisuth K, Obchoei S, Mahalapbutr P, Wongkham S. FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase. Life Sci 2021;286:120072. [PMID: 34688691 DOI: 10.1016/j.lfs.2021.120072] [Reference Citation Analysis]
519 Sittithumcharee G, Suppramote O, Vaeteewoottacharn K, Sirisuksakun C, Jamnongsong S, Laphanuwat P, Suntiparpluacha M, Matha A, Chusorn P, Buraphat P, Kakanaporn C, Charngkaew K, Silsirivanit A, Korphaisarn K, Limsrichamrern S, Tripatara P, Pairojkul C, Wongkham S, Sampattavanich S, Okada S, Jirawatnotai S. Dependency of Cholangiocarcinoma on Cyclin D-Dependent Kinase Activity. Hepatology 2019;70:1614-30. [PMID: 31077409 DOI: 10.1002/hep.30704] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
520 Mondaca S, Nervi B, Pinto M, Abou-Alfa GK. Biliary tract cancer prognostic and predictive genomics. Chin Clin Oncol 2019;8:42. [PMID: 31431036 DOI: 10.21037/cco.2019.07.06] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
521 Wongjarupong N, Assavapongpaiboon B, Susantitaphong P, Cheungpasitporn W, Treeprasertsuk S, Rerknimitr R, Chaiteerakij R. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis. BMC Gastroenterol. 2017;17:149. [PMID: 29216833 DOI: 10.1186/s12876-017-0696-4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
522 Sato K, Glaser S, Alvaro D, Meng F, Francis H, Alpini G. Cholangiocarcinoma: novel therapeutic targets. Expert Opin Ther Targets. 2020;24:345-357. [PMID: 32077341 DOI: 10.1080/14728222.2020.1733528] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
523 Delgado Maroto A, Barrientos Delgado A, Lázaro Sáez M, Hallouch Toutouh S, Práxedes González E. Primary squamous cell carcinoma of the extrahepatic bile duct: A case report. Gastroenterol Hepatol 2019;42:436-7. [PMID: 31126636 DOI: 10.1016/j.gastrohep.2019.03.003] [Reference Citation Analysis]
524 Akara-Amornthum P, Lomphithak T, Choksi S, Tohtong R, Jitkaew S. Key necroptotic proteins are required for Smac mimetic-mediated sensitization of cholangiocarcinoma cells to TNF-α and chemotherapeutic gemcitabine-induced necroptosis. PLoS One 2020;15:e0227454. [PMID: 31914150 DOI: 10.1371/journal.pone.0227454] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
525 Chang W, Wang Y, Li W, Shi L, Geng Z. MicroRNA-551b-3p inhibits tumour growth of human cholangiocarcinoma by targeting Cyclin D1. J Cell Mol Med. 2019;23:4945-4954. [PMID: 31199052 DOI: 10.1111/jcmm.14312] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
526 He J, Yang Z, Wu Z, Wang L, Xu S, Zou Q, Yuan Y, Li D. Expression of FOXP1 and FOXO3a in extrahepatic cholangiocarcinoma and the implications in clinicopathological significance and prognosis. Onco Targets Ther 2019;12:2955-65. [PMID: 31114239 DOI: 10.2147/OTT.S197001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
527 Gönül Geyik Ö, Anichini G, Ulukaya E, Marra F, Raggi C. DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives. Cells 2022;11:1463. [DOI: 10.3390/cells11091463] [Reference Citation Analysis]
528 Le Faouder J, Gigante E, Léger T, Albuquerque M, Beaufrère A, Soubrane O, Dokmak S, Camadro J, Cros J, Paradis V. Proteomic Landscape of Cholangiocarcinomas Reveals Three Different Subgroups According to Their Localization and the Aspect of Non‐Tumor Liver. Prot Clin Appl 2018;13:1800128. [DOI: 10.1002/prca.201800128] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
529 Khamko R, Daduang J, Settasatian C, Limpaiboon T. OPCML Exerts Antitumor Effects in Cholangiocarcinoma via AXL/STAT3 Inactivation and Rho GTPase Down-regulation. Cancer Genomics Proteomics 2021;18:771-80. [PMID: 34697068 DOI: 10.21873/cgp.20296] [Reference Citation Analysis]
530 Li J, Chen Q, Jin B, Shi Y, Wu X, Xu H, Zheng Y, Wang Y, Du S, Lu X, Mao Y, Sang X. Preoperative Bilirubin-Adjusted Carbohydrate Antigen 19-9 as a Prognostic Factor for Extrahepatic Cholangiocarcinoma Patients at a Single Center. Cancer Manag Res 2020;12:411-7. [PMID: 32021453 DOI: 10.2147/CMAR.S229329] [Reference Citation Analysis]
531 Zamora-Valdes D, Heimbach JK. Liver Transplant for Cholangiocarcinoma. Gastroenterol Clin North Am. 2018;47:267-280. [PMID: 29735023 DOI: 10.1016/j.gtc.2018.01.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
532 Bahra M. [Surgical treatment of distal cholangiocarcinoma]. Chirurg 2021;92:788-95. [PMID: 34232340 DOI: 10.1007/s00104-021-01453-2] [Reference Citation Analysis]